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The roles of Th1 and Th17 responses as mediators of host protection and pathology in the 
intestine are the subjects of intense research. Here we investigated a model of intestinal 
inflammation driven by the intracellular apicomplexan parasite Eimeria falciformis. Although 
IFN-γ was the predominant cytokine during E. falciformis infection in wild type mice, it was 
found to be dispensable for host defence and the development of infection-driven intestinal 
inflammation. E. falciformis-infected IFN-γR-/- and IFN-γ-/- mice developed dramatically 
exacerbated body weight loss and intestinal pathology, but surprisingly harboured fewer 
parasites. This was associated with a striking increase in parasite-specific IL-17A and IL-22 
production in the mesenteric lymph nodes and at the site of infection. CD4+ T cells were 
found to be the source of IL-17A and IL-22, which drove the recruitment of inflammatory 
neutrophils and increased tissue expression of anti-microbial peptides (RegIIIβ, RegIIIγ) and 
matrix metalloproteinase 9. Concurrent neutralisation of IL-17A and IL-22 in E. falciformis 
infected IFN-γR-/- mice resulted in a reduction in infection induced body weight loss and 
inflammation and significantly increased parasite shedding. In contrast, neutralisation of IL-
22 alone was sufficient to increase parasite burden but had no effect on inflammation and 
pathology. Treatment of an E. falciformis infected intestinal epithelial cell line with IFN-γ, 
IL-17A or IL-22 significantly reduced parasite development in vitro. Taken together these 
data demonstrate for the first time an anti-parasitic effect of IL-22 during an intestinal 
infection and suggest that IL-17A and IL-22 have redundant roles in driving intestinal 
pathology in the absence of IFN-γ signalling. 
To further develop E. falciformis as a model system, we established transfection of E. 
falciformis sporozoites using various plasmids that contain the fluorescent reporter YFP and 
the resistance marker DHTS. Sporozoites applied rectally to mice were shown to complete 
their life cycle, albeit with a lower efficiency in comparison to oral infection with oocysts. 
Furthermore, pyrimethamine was able to kill over 95 % of wild type parasites and could thus 
be used for selection of transgenic E. falciformis. Repeated in vivo selection using 
pyrimethamine and/or FACS and manual sorting led to a maximum percentage of 34 % YFP-
expressing oocysts. Microscopical tracking of YFP-expressing life cycle stages of E. 
falciformis at the site of infection ex vivo and in a cell line in vitro suggested stability of the 
introduced fluorescent reporter during asexual development of E. falciformis. Taken together, 
we demonstrate for the first time transfection of E. falciformis and provide perspectives for 





Wir nutzten in dieser Studie den apikomplexen Parasiten Eimeria falciformis als Modell. 
Unsere Ergebnisse zeigen, dass das in infizierten Wildtypmäusen dominierende Zytokin IFN-
γ für Immunschutz und für die Entwicklung der Darmpathologie entbehrlich war. E. 
falciformis-infizierte IFN-γR-/- and IFN-γ-/- Mäuse zeigten extremen Körpergewichtsverlust 
und starke Pathologie im Darm. Die Entwicklung des Parasiten in diesen Mäusen war 
überraschenderweise reduziert. Diese Beobachtungen gingen mit einer drastisch erhöhten 
Produktion von parasiten-spezifischem IL-17A und IL-22 durch CD4+ T Zellen einher. IL-
17A und IL-22 bewirkten die Einwanderung von entzündungsfördernden Neutrophilen und 
eine erhöhte Expression von antimikrobiellen Peptiden (RegIIIβ, RegIIIγ) und 
Matrixmetalloproteinase 9. Gleichzeitige Neutralisierung von IL-17A und IL-22 in E. 
falciformis-infizierten IFN-γR-/- Mäusen verringerte den Körpergewichtsverlust und die 
Darmpathologie, und führte zu einer erhöhten Ausscheidung von Parasiten. Die alleinige 
Neutralisierung von IL-22 war ausreichend, um die Parasitenlast zu erhöhen, hatte aber 
keinen Einfluss auf Körpergewichtsverlust und Darmpathologie. Die Behandlung einer E. 
falciformis-infizierten intestinalen Epithelzelllinie mit IL-17A oder IL-22 führte zu einer 
signifikant reduzierten Entwicklung von E. falciformis in vitro. Diese Daten demonstrieren 
erstmalig einen anti-parasitären Effekt von IL-22 im Darm und deuten auf redundante Rollen 
von IL-17A und IL-22 im Hinblick auf die Förderung von Darmpathologie in Abwesenheit 
von IFN-γ hin. 
Um E. falciformis als Modellsystem weiter zu entwickeln, haben wir die Transfektion von E. 
falciformis Sporozoiten mit verschiedenen Plasmiden die den Reporter YFP und den 
Resistenzmarker DHTS enthalten etabliert. Rektal in Mäuse injizierte Sporozoiten 
entwickelten sich erfolgreich zu Oocysten, wenn auch mit geringerer Effizienz im Vergleich 
zur oralen Infektion mit Oozysten. Weiterhin konnte gezeigt werden, dass Pyrimethamin über 
95 % der Wildtyp-Parasiten tötet und somit zur Selektion von transgenen E. falciformis 
eingesetzt werden kann. Wiederholte in vivo Selektion YFP-exprimierender Oozysten führte 
zu Populationen mit maximal 34 % YFP-exprimierenden Parasiten. Mikroskopische Analyse 
von YFP-exprimierenden Stadien am Ort der Infektion ex vivo und in einer Zelllinie in vitro 
deuten auf eine stabile Verteilung des fluoreszierenden Reporters während der asexuellen 
Vermehrung von E. falciformis hin. Wir demonstrieren in dieser Arbeit zum ersten Mal die 
Transfektion von E. falciformis und zeigen Perspektiven im Hinblick auf die Etablierung 
einer stabil transgenen Parasitenlinie auf. 
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In this study, the murine intestinal parasite Eimeria falciformis is used as a model to address 
immune responses at intestinal mucosal barrier surfaces during specific infections. The 
introduction will outline basics and recent advances in the knowledge on the intestinal 
immune system, with particular focus on IFN-γ and Th17 responses. Furthermore, a detailed 
introduction on murine Eimeria spp., including the life cycle, pathology of infections, 
immune responses against the parasite, genetic manipulation and in vitro culture will be 
given. Based on the current knowledge and availability of tools, the potential of murine 
Eimeria spp. to serve as a powerful model system for the investigation of immune responses 
in different parts of the intestine during infections will be highlighted and the challenges of 
the system will be pointed out. 
 
1.1. The intestinal immune system 
The gastrointestinal tract constitutes a large surface that is in close contact with commensal 
microflora, pathogens and food antigens. Thus the immune system faces the complex task to 
tolerate commensals and food antigens, while at the same time effectively preventing the 
dissemination of pathogens (1). A single layer of epithelial cells covered by a mucus layer 
forms the first line of defence at the border of host and environment (Fig. 1). The different 
cell types of the intestinal epithelium are able to produce an array of antimicrobial peptides, 
mucins, cytokines and chemokines and thus themselves can provide innate effector 
mechanisms against pathogens, and are able to induce and shape the subsequent adoptive 
immune response. Furthermore, immune cells situated directly within the epithelium 
(intestinal epithelial lymphocytes, IELs) that mostly bear the γδ T cell receptor act as sentinels 
and regulators of the immune system (2). The lamina propria situated at the basal site of the 
epithelial cell layer provides the environment for the adaptive immune system, including T 
cells, mainly IgA-secreting B cells, dendritic cells, macrophages and stromal cells (Fig. 1). 
Antigen presenting cells migrate through the lympathic vessels to the mesenteric lymph 
nodes, where they come into close contact with T and B cells. Subsequently, primed T cells 
and IgA-secreting B cells migrate back to the intestine where they exert their effector 
functions (3). Furthermore, highly organised lymphoid structures, like M cells and Peyer’s 
Patches in the small intestine as well as lymphoid patches and caecal patches in the large 








Fig. 1. Anatomy of the intestinal immune system. The intestinal epithelium is a single cell layer that consists 
of absorptive enterocytes, mucus producing goblet cells, and secretory cells, like paneth cells in the small 
intestine. All cells differentiate from epithelial stem cells that are localised to the base of the crypts. The 
epithelium is covered by a thick mucus film and commensal microbiota, and forms a physical barrier between 
the gut lumen and the underlying lamina propria that is made up of T cells, mainly IgA secreting B cells, 
dendritic cells, macrophages and stromal cells. Lympathic vessels connect the intestinal mucosa with the 
mesenteric lymph nodes. Figure taken from (3). 
 
1.2. Arms of the immune response 
As described above, the intestinal immune system consists of many cell types, with T cells 
being one of the most important players of the adaptive immune system. T cells can be 
divided into several subsets, depending on their cytokine profile and the expression of 
characteristic master transcription factors. The pioneering work by Mosmann and Coffman 
described two subsets of T cells, Th1 and Th2, which were characterised by secretion of IFN-
γ (Th1) and IL-4 (Th2) (4). Whereas Th1 cells were described to be effective against 
intracellular pathogens like viruses, bacteria and protozoan parasites, Th2 cells were shown to 
be involved in the defence against extracellular parasites like worms (5). However, the system 
has recently been shown to be much more diverse with regulatory T cells, Th17 cells, 
follicular helper cells and Th9 cells being identified as additional T cell subsets (6). 




a high potential of plasticity, which adds further complexity to the system (7). An overview 
on the differentiation of the different subsets, including their master transcription factors and 
cytokine profiles is given in Fig. 2. As they are of high relevance to this study, more details 
on the development and function of Th1 and Th17 subsets and to a lesser extent on Th2 and 




Fig. 2. T helper cell differentiation. The figure depicts the current state of knowledge on Th cell differentiation 
into Th1, Th2, Th17, Treg, Th9 and TFH lineages. Shown are the factors needed for polarisation towards and 
stabilisation of each subset, transcription factors that are expressed in the certain subset and the characteristic set 
of cytokines secreted by these cells. Figure taken from (6). 
 
1.2.1. Th1 immune responses and IFN-γ  
Polarisation of naïve T cells towards the Th1 lineage is initially driven by IL-12 (p35/p40) 
and IL-18, which are secreted by dendritic cells (DCs) and macrophages (Mø) upon antigen 
encounter. IL-12 and IL-18 drive the early production of IFN-γ by DCs, Mø and NK cells, 
which amplifies the innate response in a positive feedback loop (8). Additionally, IFN-γ from 




naïve T cells towards the Th1 programme by inducing the expression of the Th1 master 
transcription factor T-bet (9). Expression of T-bet leads to further activation of the IFN-γ gene 
and promotes the expression of the IL-12Rβ2 chain by these T cells, which renders them 
responsible to IL-12 from innate cells. IL-12 receptor binding activates STAT4, which in turn 
drives the expression of IFN-γ and the IL-18 receptor. Signalling through IL-12 and IL-18 
receptors further increases IFN-γ levels and drives production of other proinflammatory 
mediators such as TNF-α and IL-2 that strengthen the Th1 profile (8). Failure to control and 
terminate these effector responses can lead to inflammatory disorders, like inflammatory 




Fig. 3. Th1 cell polarisation. Development of Th1 cells from naïve T cells is driven by IL-12, IFN-γ and IL-18 
from innate cells and leads to the expression of the Th1 master transcription factor T-bet and STAT4 as well as 
IL-18R and IL-12Rβ2. Responsiveness to IL-18 and IL-12 amplifies the TCR-independent production of IFN-γ 
by the Th1 cells, which in turn leads to the production of other Th1 related mediators such as IL-6 and TNF-α 
that drive the proinflammatory response. Figure taken from (8). 
 
IFN-γ is classically considered the prototypic Th1 cytokine and has important functions in 




including Eimeria spp., Toxoplasma gondii, Leishmania major, Trypanosoma cruzi and 
Plasmodium spp. (11-16). IFN-γ is a potent pro-inflammatory cytokine derived from multiple 
cells of both the innate and adaptive immune system including CD4+ Th1 cells, CD8+ T cells 
and Natural Killer (NK) cells. As described above, IFN-γ leads to the polarisation of naïve T 
cells towards the Th1 programme and the production of pro-inflammatory mediators, such as 
IL-12, IL-6 and TNF-α.  Furthermore, IFN-γ can exert its effector functions by direct 
activation of immune genes through STAT1 including genes encoding for antimicrobial 
molecules, chemokines, cytokines, phagocytosis receptors and antigen-presenting molecules 
(17). Macrophages that are activated by IFN-γ can kill pathogens via induction of reactive 
nitrogen intermediates (RNI, iNOS) and reactive oxygen species (ROS) (16). 
In addition to its host protective function, IFN-γ is also involved in driving immunopathology 
in response to microbial stimuli or pathogen-induced tissue damage. IFN-γ from CD4+ T cells 
mediates small intestinal necrosis in infections with the apicomplexan parasite Toxoplasma 
gondii and has also been shown to be involved in the development of inflammatory disorders 
of the intestine, such as various forms of IBD (18, 19). 
On the other hand, IFN-γ can also prevent overt pathology through various effector 
mechanisms. After initially driving the inflammatory response, IFN-γ was shown to 
autonomously limit the effector cell population via the induction of the inducible nitric oxide 
synthetase (iNOS) and thus self-limiting immunopathology (20). Amelioration of intestinal 
inflammation during IL-23 mediated colitis was mediated by IFN-γ through inhibition of IL-
23 expression (21). During mycobacterial infection, IFN-γ from nonhaematopoietic cells was 
essential to prevent neutrophilic lung inflammation by inhibiting Th17 responses, most likely 
by induction of indoleamine-2,3-dioxygenase (IDO) (22). Attenuation of the expression of 
genes that encode tissue destructive mediators such as matrix metalloproteinases is another 
regulatory mechanism of IFN-γ (17).  
The almost ubiquitous expression of the IFN-γ receptor underlines its importance. The 
functional IFN-γ receptor complex consists of two IFN-γR1 chains (α-subunits) and two IFN-
γR2 chains (β-subunits). The extracellular portion of the IFN-gR1 chain contains the ligand-
binding domain whereas the intracellular portions of IFN-γR1 and 2 are needed for signal 
transduction (Fig. 4). Upon binding of an IFN-γ homodimer, the two IFN-γR1 subunits 
dimerise and the IFN-γR2 subunits are recruited to form the active receptor complex. The 
inactive Jak1 and Jak2 enzymes carried by the IFN-γR1 and 2 subunits come in close 




residue and the formation of paired STAT1 docking sites. Subsequently, two STAT1 
molecules bind these sites, get phosphorylated by the JAK enzymes, dissociate and upon 
phosphorylation form the active STAT1 homodimer. This complex is then translocated to the 
nucleus, where it binds to promoter elements of INF-γ inducible genes, effecting their 
expression (23). 
Disruption of IFN-γ signalling has severe consequences for the host. Mice that have disrupted 
IFN-γ genes or are lacking a functional IFN-γ receptor display drastically enhanced 
susceptibility to pathogens, including Mycobacterium bovis, Listeria monocytogenes and 
Leishmania major and also have impaired immune cell functions such as uncontrolled T cell 
proliferation (11, 24). 
Taken together, IFN-γ is a multifunctional cytokine with critical functions in host defence 
against intracellular pathogens and immune homeostasis. Failure to control IFN-γ mediated 










Fig. 4. IFN-γ  receptor signalling. Binding of an IFN-γ homodimer to the IFN-γR1 subunits leads to the 
recruitment of the IFN-γR2 subunits and thus the formation of the functional receptor complex. Transactivation 
and phosphorylation of the JAK1 and JAK2 enzymes on the IFN-γR1 and IFN-γR2 subunits enables binding of 
STAT1 that forms an active homodimer and upon phosphorylation translocates to the nucleus, where it initiates 
the transcription of IFN-γ responsible genes. Figure taken from (25). 
 
1.2.2. Th17 immune responses 
This recently discovered arm of the immune response is subject to intense research, often 
focusing on the two major Th17 cytokines IL-17A and IL-22 (26). Differentiation of Th17 
cells, which characteristically express the master transcription factor retinoic acid-related 
orphan nuclear receptor γt (RORγt), is driven by IL-6, TGF-β and IL-21 and stabilised by IL-
23 (27-30). IL-23 closely links Th1 and Th17 responses, as IL-12p40 constitutes one subunit 




helper cells is generally described to be important in the defence against extracellular 
pathogens and fungi. For example, the two major Th17 cytokines IL-17A and IL-22 have 
host-protective roles in bacterial infections with Klebsiella pneumoniae, Citrobacter 
rodentium and Staphylococcus aureus, and IL-22 is critical in the first line defence against the 
fungal pathogen Candida albicans (32-36). On the other hand, Th17 responses have been 
ascribed important roles in autoimmune inflammation. Induction of GM-CSF by IL-23 and 
RORγt was shown to non-redundantly drive experimental autoimmune encephalomyelitis 
(EAE) (37, 38). Furthermore, IL-17A and IL-22 have been implicated in the development of 
colitis in humans and in murine models (39, 40), and IL-23 mediated intestinal 
immunopathology through IL-22 and matrix metalloproteinase 2 in infections with the 
apicomplexan parasite Toxoplasma gondii (41). 
Thus, depending on the context, Th17 responses can have protective as well as pathological 
functions. Furthermore, Th17 mediated host protection is generally described to be effective 
against extracellular pathogens, such as bacteria and fungi. However, little is known about the 
roles of IL-17 and IL-22 in the defence against intracellular protozoan parasites. 
 
The cellular subset “Th17” was named after IL-17A that was originally described as cytotoxic 
T lymphocyte associated antigen 8 (CTLA8). To date the IL-17 cytokine family contains six 
members (IL-17 A, B, C, D, E and F), from which IL-17A and F are the most intensively 
studied cytokines (42). Initially described to be produced by CD4+ T cells, IL-17A was 
subsequently shown to be secreted by many other cell types, including NK cells, γδ-T cells, 
CD8+ T cells, macrophages and different types of innate lymphoid cells (43). The cytokine 
receptor for IL-17A is expressed ubiquitously, including on intestinal epithelial cells, which is 
of particular importance in the context of this work (44). 
IL-17A and F have been shown to potently induce the activation and recruitment of 
neutrophils to the site of infection (42). Furthermore, the cytokines can induce the expression 
of many immune genes, including matrix metalloproteinases, antimicrobial peptides, 
chemokines and cytokines, leading to host protective as well as pathological immune 







Fig. 5. Functions of IL-17A and IL-17F. Antigen- or pathogen contact of antigen presenting cells (APCs) leads 
to the production of cytokines such as TGF-β, IL-1, IL-23 and IL-6, which induce production of IL-17A and IL-
17F by various innate and epithelial cell types and initiate priming of Th17 cells as well as activation of B cells 
and macrophages. Production of proinflammatory cytokines and other immune mediators, including 
antimicrobial peptides, matrix metalloproteinases, chemokines and cytokines drives neutrophil recruitment, 
tissue destruction and killing of pathogens, thus resulting in host protection and/or disease development. Figure 
taken from (42). 
 
IL-22 belongs to the IL-10 family of cytokines and is produced by CD4 T cells, NK cells, γδ-
T cells and by recently described innate lymphoid cells, such as lymphoid tissue inducer cells 
and NKp46+ cells (45). In contrast to the ubiquitously expressed IL-17A receptor, expression 
of the IL-22 receptor is limited to cells of non-hematopoietic origin in several tissues, 
including intestine, skin, lung, liver, kidney and pancreas (46). 
IL-22 is a potent inducer of antimicrobial peptides (AMPs), such as members of the 
regenerating islet derived protein family III (RegIIIβ, RegIIIγ), which are known to be potent 
effectors against gram positive bacteria in the intestine (47). In the skin, stimulation of 
keratinocytes by IL-22 leads to the expression of ß-defensins and AMPs of the S100 family, 
again demonstrating a pivotal role for IL-22 in host defence at barrier surfaces (48). Thereby, 
IL-22 can act synergistically or additively with IL-17A and IL-17F (32, 48). However, in 
some settings, IL-22 can also promote pathology, as shown by the development of an IL-22 
dependent ileitis after oral infection with T. gondii (41). In contrast, IL-22 also has crucial 
functions in tissue repair. In the intestine, IL-22 dependent induction of STAT3 in intestinal 
epithelial cells was shown to induce wound healing and production of protective mucus, thus 




Taken together, IL-22 is a multifunctional cytokine with strictly context-dependent functions 
that are determined by the inflammatory settings IL-22 is expressed in and the specific 




Fig. 6. Functions of IL-22 at barrier surfaces. IL-22 has crucial functions in host defence, inflammation, tissue 
protection and wound repair at epithelial barrier sites, such as the skin (a), airway (b) and respiratory tract (c). 
The functions depend strongly on the context in which IL-22 is expressed and the respective tissue 
microenvironment. Figure taken from (45). 
 
1.2.3. Regulatory T cells (Tregs) 
This T cell population was initially characterised by the expression of the forkhead box P3 
transcription factor (Foxp3). CD4+ CD25+ Foxp3+ Tregs are classically divided in naturally 
occurring Tregs (nTregs) that are thymus derived and inducible Tregs (iTregs), which 
differentiate in the periphery under the influence of TGF-β and retinoic acid (51). However, 
recently additional populations of peripheral Tregs have been described, including Th3 cells 
(CD4+ TGF-β+ Foxp3+) that produce high levels of TGF-β and T regulatory type 1 (Tr1) cells 
that do not express Foxp3 but IL-10, and are of particular importance in the intestine (52). 




the limitation of effector T cell responses and induction of oral tolerance, thus preventing 
immunopathology and autoimmunity (52, 53). 
 
1.2.4. Th2 immune responses 
Development of Th2 cells is driven by IL-4 mediated activation STAT6 and subsequent 
expression of the master transcription factor GATA3 that leads to secretion of IL-4, IL-5 and 
IL-13 and activation of the humoral immune response (54). Th2 cells have important 
functions in the defence against extracellular parasites such as helminths (55). Effector 
mechanisms include opsonisation by antibodies and expulsion of worms through increased 
epithelial cell turnover and mucus production (56, 57). However, Th2 responses can also be 
harmful to the host. In asthma, massive production of Th2 cytokines leads to eosinophilic 
inflammation and airway hyperreactivity (58). Furthermore, elevated levels of Th2 cytokines 
are involved in the development of ulcerative colitis (59). 
 
1.3. Matrix metalloproteinases (MMPs) 
This family of proteases can be secreted by various cells, including neutrophils, mesenchymal 
cells, T cells, monocytes and macrophages (60). In addition to their role in turnover of 
extracellular matrix, MMPs possess important roles in host defence, intestinal inflammation 
and tissue destruction that are mediated e.g. by proteolytic activation of antimicrobial 
peptides, chemokines and growth factors (61, 62).  
The two MMPs 2 and 9, also known as gelatinases A and B, have been shown to be involved 
in the mediation of pathology in various models of intestinal inflammation. Epithelial-derived 
MMP-9 was responsible for the pathology in DSS-induced colitis in mice, whereas ileitis after 
infection with T. gondii was mediated by IL-22 induced expression of MMP-2 (41, 63). Th17 
cytokines are also potent regulators of MMPs. IL-23 has been shown to induce neutrophil 
influx and high levels of MMP-9 in an airway inflammation model and IL-17 upregulated the 
expression of various MMPs and chemokines, including MMP-9 and granulocyte chemotactic 





1.4. Antimicrobial peptides (AMPs) 
Antimicrobial peptides are small polypeptides (< 100 a) that are mostly positively charged, 
possess an amphipathic structure and thus interact with and disrupt bacterial cell membranes 
(66). From the large number of different AMPs defensins and regenerating islet derived 
proteins III (RegIII) are of particular interest in the context of this study. 
Mammalian defensins - classified into three groups (α, β, θ) - are cationic peptides with 
strong microbicidal activity. ß-defensins are produced in the large intestine, whereas α-
defensins localise to the small intestine. These AMPs are stored in granules of neutrophils and 
paneth cells and can be secreted by monocytes, macrophages and intestinal epithelial cells 
(66). Common to all defensins is the generation of the active form from an inactive precursor 
by proteolytic cleavage.  For example, murine α-defensins are processed into their active 
forms by MMP-7 (67). Defensins possess important roles in host defence, wound healing and 
control of the microbiota (68). 
The family of regenerating islet-derived proteins (Reg) is a diverse family of secreted C-type 
lectins, which is classified into groups I–IV. Two members of group III, RegIIIβ and RegIIIγ, 
are of special interest to this study, as they are produced by intestinal epithelial cells after 
mucosal damage, pathogen encounter and IL-22 induction (34). The potential contribution to 
host protection is highlighted by the ability of RegIIIγ to mediate lysis of gram-positive 
bacteria after binding to peptidoglycan in their outer cell wall (47). 
Taken together, AMPs  are important for the regulation of the composition of the intestinal 
microbiota and the defence against pathogens, thus contributing to immune homeostasis and 
preventing mucosal damage. 
 
1.5. The intestinal apicomplexan parasite Eimeria falciformis 
Eimeria falciformis is an intracellular protozoan parasite specifically adapted to the murine 
caecum and proximal colon, where it develops a self-limiting infection in epithelial cells of 
the crypts (69, 70). The coccidian parasite belongs to the phylum of Apicomplexa that 
contains major human pathogens like T. gondii, Plasmodium spp. and Cryptosporidium 
parvum as well as other genera of parasites that are of economic importance for animal 





1.5.1. Economical relevance 
Infections with Eimeria spp. (coccidiosis) are of economic relevance, particularly in the 
poultry industry with the costs attributed to lost revenue and drug treatment estimated to be in 
excess of £2 billion per year worldwide (71). To date, control of coccidiosis mainly relies on 
prophylactic chemotherapy. However, increasing health awareness and demand for organic 
produce has raised consumer concerns regarding drug residues in poultry products, which 
increases the pressure to ban the use of anticoccidials in animal fed. In Europe, some 
chemical anticoccidials have already been prohibited, thus limiting the portfolio of available 
drugs (71). Under these circumstances, interest in the use of vaccines is growing steadily. 
Both, live vaccines and live-attenuated vaccines are successfully used, while attenuated 
vaccines are preferred due to their higher safety (72). A major drawback of live-attenuated 
vaccines is the need for expensive oocyst production in chickens. Thus, the development of 
safe and cost-effective recombinant vaccines is crucial for sustainable vaccination in future. 
Recently, a subunit vaccine (CoxAbic®) that is composed of purified antigens from the wall 
forming bodies of E. maxima has been extensively tested in field trials (73). However, 
production of this vaccine is still expensive and laborious, because native antigens have to be 
affinity purified from parasites. The suitability of recombinant gametocyte antigens for use in 
subunit vaccines is subject to current research (74). 
 
1.5.2. Murine Eimeria spp. as a model system for intestinal immune responses 
Eimeria spp. parasitize a broad spectrum of vertebrates, but each species is strictly host and 
habitat specific (75). The two murine species E. falciformis and Eimeria pragensis colonise 
the caecum and proximal colon, whereas Eimeria vermiformis and Eimeria papillata develop 
in epithelial cells of the small intestine of mice. Thus, these species can serve as models for 
avian Eimeria spp., such as Eimeria tenella (caecum) and Eimeria maxima (small intestine). 
Infections with Eimeria spp. are local, self-limiting and cause transient weight loss and 
intestinal pathology. E. falciformis, the natural murine species used in this study, induces 
strong inflammation in the caecum and colon and thus has many parallels with colitic disease 
(76). The mouse model offers additional advantages, as a large set of immunological tools and 
numerous genetically manipulated mouse strains are available. The characteristics described 






1.5.3. Life cycle of E. falciformis 
The monoxenous life cycle of Eimeria spp. resembles the sequence of schizogony, gamogony 
and sporogony that are characteristic for the Apicomplexa (Fig. 7). Mice take up sporulated 
oocysts via the faecal-oral route and the oocyst wall most likely gets digested by the influence 
of pepsin during stomach passage (77). Sporocysts get liberated and during passage of more 
distal parts of the intestine, motile sporozoites actively excyst from the sporocyst. E. 
falciformis sporozoites invade epithelial cells of the Crypts of Lieberkuehn and – residing in a 
parasitophorous vacuole - undergo 3-4 rounds of asexual replication (schizogony) before they 
enter the sexual phase of their life cycle. Macro- and microgametes fuse and the resulting 
zygote subsequently develops into an unsporulated oocyst, which is shed with the faces after a 
mean prepatency phase of 6 days (69, 70). Sporulation takes place in the environment within 
3 to 5 days and leads to development of infective oocysts containing 4 sporocysts that harbour 




Fig. 7. Life cycle of Eimeria falciformis. Sporulated oocysts (I) harbour sporocysts containing motile 
sporozoites (II) that undergo several rounds of schizogony (III) in intestinal epithelial cells. Merozoites (IV) 
develop into micro- (V) and macrogametes (VI) that fuse to form the zygote (VII), which eventually develops 





1.5.4. Invasion of host cells 
Invasion of host cells by apicomplexan parasites is facilitated by a set of organelles that form 
the apical complex (Fig. 8). Rhoptry and microneme proteins are sequentially discharged 
upon contact to the host cell membrane and, forming a moving junction, drive the non-
destructive invasion into the host cell, accompanied by the development of a parasitophorous 
vacuole (79). Components of the invasion machinery have been characterised in several 
apicomplexan parasites, including Eimeria spp. (79, 80). A comparative analysis of the 
proteome of different life cycle stages of the avian parasite E. tenella shed light on presence 
and dynamics of proteins involved in the invasion process, among them microneme and 
rhoptry neck proteins (81). Recently, the promoter of the E. tenella microneme protein 1 
(EtMIC1) was successfully used to drive YFP genes in the generation of fluorescent reporter 




Fig. 8 Sporozoite of Eimeria spp. Eimeria sporozoites possess the general structure of apicomplexan parasites, 
including the apical complex with conoid, rhoptries and micronemes. Characteristic for Eimeria sporozoites is 
the presence of a small anterior refractile body and a large posterior refractile body. Figure taken from (83). 
 
1.5.5. Pathology of murine Eimeria infections 
Infections with Eimeria cause coccidiosis, a disease during which animals develop a transient, 
mild to severe pathology depending on the infection dose and the pathogenicity of the 




anorexia, dysentery and rapid weight loss (76). The symptoms are most pronounced eight to 
ten days post infection, correlating with the peak days of oocyst shedding. As the infection is 
self-limiting and parasites are cleared out rapidly, infected animals quickly recover. 
Histopathological analysis of the site of infection reveals massive cellular infiltrates, edema, 
crypt hyperplasia and loss of crypt architecture (76). Similar observations were made with the 
murine small intestinal species E. vermiformis, documenting influx of neutrophils and 
mononuclear cells to the site of infection (84). In part, the observed pathology can be caused 
by the destruction of epithelial cells during development of Eimeria spp. in particular by the 
rapid replication of merozoites during asexual development (76, 85). However, it seems likely 
that the major part of the observed pathology is due to inflammatory immune responses. 
Production of TNF-α was shown to correlate with the generation of immunopathology in 
infections with several Eimeria species (86, 87). 
There are only few reports on the regulation of pathology in infections with Eimeria spp. 
Depletion of IFN-γ in infections with the large intestine-dwelling parasite E. pragensis did not 
abrogate host defence, but exacerbated clinical signs of infections, thus suggesting a 
regulatory role for IFN-γ (88).  Immune cells that reside directly in the infected epithelium 
can also limit pathology during infections with Eimeria spp. The exacerbated pathology 
observed in E. vermiformis infected γδ+ cell deficient mice was most likely due to a failure to 
limit αβ-T cell responses (89). Furthermore, intraepithelial lymphocytes (IEL) were shown to 
maintain epithelial barrier function in E. vermiformis infection through expression of 
junctional molecules (87). 
Taken together, information on the mechanisms of pathology in infections with Eimeria spp. 
is rare and mostly coming from early, descriptive studies, thus not including recent advances 
in the understanding of the intestinal immune system. Hence, there are no reports on the role 
of other cytokines, particularly on the involvement of the IL-17 and IL-22 in infections with 
this intestinal intracellular protozoan parasite. 
 
1.5.6. Host immune response against murine Eimeria spp. 
There are four Eimeria species being used in the mouse model. E. vermiformis and E. 
papillata that infect epithelial cells of the small intestine and the large intestine-dwelling 
species Eimeria falciformis and Eimeria pragensis. It is important to note that this site 




account for the observed differences in the immune responses. Thus, data will be discussed in 
context with the Eimeria species used. 
Infections with Eimeria spp. induce a strong Th1 response and lead to a protective immunity 
against challenge infections, with a species-dependent degree of protection. Whereas a single 
infection with E. vermiformis can lead to sterile immunity against challenge infections, 
several infections with E. falciformis or E. pragensis are required to achieve the same degree 
of protection (88, 90). Infections with Eimeria spp. are accompanied by strong humoral and 
cellular immune responses, the latter being shown to be essential for limitation of the primary 
response and for development of immunity against challenge infections. αβ-T cells were 
shown to be crucial for the limitation of primary and challenge infections as well as the 
development of immunity against E. vermiformis (89, 91). Similarly, athymic (nude) mice 
infected with E. falciformis var. pragensis shed significantly more oocysts during primary 
infections and displayed impaired protection against subsequent infections (92). The same 
observations were reported after infection of nude mice with E. vermiformis (93). Partial 
depletion of T- and NK-cells using monoclonal Thy-1.2 antibodies in infections with E. 
falciformis resulted in increased reproduction and prolonged patency (94). 
The cellular subsets that mediate protection and the underlying effector mechanisms are not 
yet fully understood. Furthermore, immune responses differ between Eimeria species, in 
particular when small intestinal and large intestinal species are compared. Adoptive transfer 
of CD8+ T cells was shown to mediate partial protection against reinfection with E. 
falciformis (12). Similar results were obtained for E. pragensis, where oocyst production was 
increased after depletion of CD4+ T cells during primary infection or CD8+ T cells during 
challenge infection (95). Furthermore, CD4+ T cells were crucial for the development of 
protective immunity against homologous challenge infections. Thus, CD4+ T cells control 
primary infections and the development of immune protection, whereas CD8+ T cells limit 
parasite replication during challenge infections with these large intestinal Eimeria spp. CD4+ 
T cells also control primary infections and development of immune protection in infections 
with the small intestinal species E. vermiformis. In contrast to the large intestinal species, 
depletion of neither CD4+ nor CD8+ T cells significantly influenced parasite replication 
during challenge infections, but the presence of αβ-T cells was still essential (95, 96). 
Effector mechanisms against intracellular parasites include the production of reactive nitrogen 
intermediates, Fas ligand-mediated apoptosis of the host cell and lysis of the host cell by 
cytotoxicity. However, non of these mechanisms plays a role in infections with E. 




Fas ligand or perforin, when compared to wild type controls (96).  Inhibition of invasion and 
host cell lysis also seem to be not involved in the immunity against E. falciformis, as the 
number of initial intracellular parasite stages at the site of infection was comparable between 
immune and primarily infected mice (90). Interestingly, developing schizonts degenerated 
inside their host cells, thus suggesting a role for cell mediated immune mechanisms other than 
cytotoxicity. 
Taken together, further research that takes into account recent advances in the understanding 
of the intestinal immune system is needed to clarify the immune effector mechanisms that 
control infections with murine Eimeria spp. 
 
1.5.7. The role of IFN-γ  in infections with murine Eimeria spp. 
Infection of mice lacking IFN-γ or a functional IFN-γ receptor with the small intestinal 
parasite E. vermiformis has demonstrated an essential role for IFN-γ in primary infections, 
whereas it is dispensable for the development of immune protection and during secondary 
infections (96). Depletion of IFN-γ with monoclonal antibodies in infections with E. 
vermiformis led to similar results (88, 97). Consistent with these observations, recombinant 
IFN-γ inhibited the development of E. vermiformis in epithelial cells and fibroblasts in vitro 
(98). In contrast, depletion of IFN-γ in primary infections with the large intestine-dwelling 
species E. pragensis did not influence parasite development and development of immunity 
against challenge infections. However IFN-γ seemed to be involved in the limitation of 
pathology as depletion of the cytokine exacerbated the clinical signs of infection. 
Furthermore, partial immunity to challenge was reduced, when IFN-γ was neutralised 2 h 
prior to challenge (88). In previous studies in our group adoptive transfer of IFN-γ-producing 
CD8+ T cells from E. falciformis-infected mice was sufficient to confer partial protection 
against subsequent challenge infections (12). However, it is not known if IFN-γ is essential 
and if other cytokines contribute to the protective immune response. 
 
1.5.8. Genetic Manipulation of Eimeria spp. 
Transfection via electroporation is the method of choice in genetic manipulation of 
apicomplexan parasites. Among them Toxoplasma gondii has been the first species that was 
transfected and subsequently became a powerful model organism (99). The main advantages 




set of molecular tools available. Reverse and forward genetics are very well established for T. 
gondii (100). Later on, stable transfection of Plasmodium falciparum, Plasmodium berghei 
and Plasmodium yoelii was successfully established and numerous groups work on strategies 
to improve these systems (101-104). Genetic manipulation of Sarcocystis neurona, a 
coccidian parasite closely related to T. gondii, has also been successful (105). Genetic 
manipulation of Eimeria is still in its initial stage and many tools that are used in the model 
apicomplexan parasite T. gondii are not yet available for Eimeria spp. A main reason is the 
lack of an efficient system for in vitro propagation of Eimeria spp. For transfection, 
sporozoites have to be isolated from the oocyst, as this is not accessible for transfection due to 
its tough cyst shell. Transfected parasites have to be passaged in vivo, purified from the faeces 
and screened microscopically in a time consuming process. Potential recombination events 
during the sexual phase of the life cycle add further complexity to the system. Despite these 
challenges, significant progress in the transfection of Eimeria spp. has been made over the last 
years. 
In an initial study the avian parasite E. tenella was transiently transfected with constructs 
containing the lacZ gene. Transfected sporozoites successfully invaded host cells in vitro and 
expressed ß-galactosidase during the first asexual stages of the life cycle (106). A more recent 
study confirmed these results by transiently expressing fluorescent reporter genes in E. tenella 
(107). Subsequently, substantial progress has been made in establishing a stable transfection 
system. Using a mutated version of the dihydrofolate reductase-thymidilate synthase enzyme 
complex (DHFR-TSm2m3) as a selection marker that conferred resistance to pyrimethamine 
and/or FACS sorting, transgenic lines of E. tenella, expressing various fluorescent reporter 
proteins were brought to a purity of  > 95% (82, 108). Furthermore, application of restriction 
enzyme mediated insertion improved transfection efficiency and genomic integration of the 
introduced genes (82, 109, 110). However, the studies described above were all carried out in 
the avian system and the only report on the transient expression of fluorescent reporter genes 
in a rodent system comes from transfection of the rat parasite Eimeria nieschulzi (111). 
Successful transfection of murine Eimeria spp. remains to be shown.  
 
1.5.9. In vitro culture of Eimeria spp. 
In contrast to in vitro culture of the most versatile apicomplexan model parasite T. gondii, 
which resembles a continuous and exponential asexual replication of the tachyzoite stage 
from the intermediate host, Eimeria spp. complete their genetically predetermined life cycle 




Generally, most cell lines are successfully invaded by Eimeria spp., but further development 
occurs only in some cells. Attempts to complete the life cycle of Eimeria in vitro have only 
been successful for the avian species Eimeria tenella (112). However, the yield in oocysts 
from this culture in primary chicken kidney cells (PCKCs) was very low and does not allow 
replacement of in vivo passage in animals. 
The murine, small-intesinal parasite Eimeria vermiformis has been cultured until the first 
asexual generation (schizont) in whole mouse embryo cells, bovine kidney cells and Madin-
Darby bovine kidney cells (113). Furthermore, fibroblast-like cells (L-929) and rat epithelial-
like cells (RATEC) were used to assess the influence of IFN-γ on the invasion and 
development of E. vermiformis in vitro (98). The large intestine-dwelling murine species 
Eimeria falciformis has been shown to develop to the first asexual generation in various cell 
lines, among them MODE-K and STAT1-/- cells (114). Eimeria separata, which infects small 
intestinal epithelial cells of rats, can develop until the second asexual generation in VERO 
cells in vitro (111). Eimeria bovis, a species of cattle, has also been successfully cultured to 
the first asexual generation in bovine umbilical vein endothelial cells (BUVEC) and bovine 
fetal gastrointestinal cells (BFGC) in vitro (115). The completion of the life cycle, i.e. the 
development of oocysts, was occasionally observed in BFGC. However, the life cycle of E. 
bovis differs substantially from that of avian and rodent species of Eimeria. 
Thus, further work is needed to develop an efficient in vitro culture system in particular for 
murine Eimeria spp. Preferentially, primary cells and/or cell lines should be derived from the 
murine intestine to mimic the parasites physiological microenvironment and to be able to 
address immunological questions. 
AIMS OF THE STUDY 
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2. Aims of the study 
In a previous study in our group adoptively transferred CD8+ IFN-γ-producing T cells from 
Eimeria falciformis-infected mice were shown to mediate partial immunity against challenge 
infections (12). To determine if IFN-γ is essential for host protection during E. falciformis 
infection and to further characterise its role in this intestinal infection model as well as to 
address the possible importance of other cytokines, we aimed to assess parasite development, 
body weight loss, histological and immunological parameters in infections of mice deficient 
in IFN-γ (IFN-γ-/-) and its receptor (IFN-γR-/-) in comparison to C57BL/6 wild type (wt) mice. 
Additionally, we wanted to establish the first steps of the E. falciformis life cycle in a murine 
intestinal epithelial cell line to address immunological questions in vitro. Furthermore, we 
aimed to establish a transfection system for E. falciformis, as parasites expressing fluorescent 
reporter genes could be tracked microscopically directly at the site of infection in vivo and in 






3.1. Analysis of host-pathogen interactions in E. falciformis-infected IFN-γ  
and IFN-γR deficient mice 
 
3.1.1. IFN-γ  and IFN-γR deficient mice show increased weight loss and intestinal 
pathology following E. falciformis infection 
To further characterise the role of IFN-γ in infections with E. falciformis, inflammation-
induced pathology and infection-associated body weight loss were assessed after infection of 
mice deficient in IFN-γ or its receptor in comparison to wt mice. In contrast to wt mice, which 
only transiently lost weight during primary infection (days 8-10 p. i., Fig. 9A), IFN-γR-/- mice 
showed a dramatically exacerbated body weight loss at day 10 p. i. (IFN-γR-/- 18.7 ± 1.4 % vs 
wt 2.2 ±1.7 %, p≤0.01, Fig. 9A). Morbidity was also clearly aggravated in IFN-γR-/- mice, 
which was apparent from bloody faeces, crouched posture and ruffled fur (data not shown). 
Infection of mice lacking the cytokine (IFN-γ-/-) resulted in a comparable body weight loss 
and signs of morbidity at day 10 p. i. (IFN-γ-/- 19.7 ± 1.0 % vs wt 2.4 ± 1.0 %, p≤0.001, Fig. 
9B). Histological analysis of infected caecal tissue during primary infection revealed 
increased pathology in IFN-γR-/- mice compared to wt mice as characterised by marked 
inflammatory infiltrates, ulceration, epithelial hyperplasia, goblet cell depletion and crypt loss 
(Fig. 9C). 
The increased infection-induced pathology was even more pronounced during secondary 
infections of IFN-γR-/- mice. A primary dose of 50 oocysts followed by a challenge infection 
with the same dose led to a mortality of 100 % in IFN-γR-/- mice (Fig. 9A).  In contrast WT 
mice showed no significant weight loss during challenge infection. The increase in infection 
induced pathology in secondary compared to primary infections was confirmed by 
histopathological analaysis of infected caecal tissue, which shows extreme inflammatory 
infiltrates, ulceration, abundant crypt loss and destruction of intestinal architecture (Fig. 9C). 
Interestingly, MLN and spleen cells from IFN-γR-/- mice that were isolated at day 10 after 
primary infection and restimulated with E. falciformis sporozoite antigen showed a 14.9 fold 
(MLN) and 6.9 fold (spleen) increase in proliferation in comparison to cells isolated from wt 
mice (p≤0.01, Fig. 9D). The drastically enhanced proliferation of isolated lymphocytes 




account for the observed immunopathology and suggests an important regulatory role for 




Fig. 9. Bod weight loss and intestinal pathology in wt, IFN-γR-/- and IFN-γ-/- mice infected with Eimeria 
falciformis. (A) Body weight loss of wt (circles) and IFN-γR-/- (triangles) mice after primary (1st, open symbols) 
and challenge (2nd, closed symbols) infections with 50 E. falciformis oocysts. Mice were euthanised upon loss of 
20 percent body weight (†). (B) Body weight loss of wt (circles) and IFN-γ-/- (triangles) mice after primary 
infection with 50 E. falciformis oocysts. (C) Hematoxylin & Eosin (H & E) stained caecal thin sections of wt and 
IFN-γR-/- mice after primary and challenge infections with 50 E. falciformis oocysts. (D) Parasite antigen 
specific proliferation of mesenteric lymph node cells (MLNC) and spleen cells of wt (shaded bars) and IFN-γR-/- 
(open bars) mice isolated 10 days after infection with E. falciformis and measured by 3H-thymidine 
incorporation. Data shown are mean ± SEM of 6-8 mice per group and representative of 4 (IFN-γR-/-) and 2 





3.1.2. Signalling via IFN-γ Receptor I is not required for the control of parasite 
replication or for the development of immunity 
As IFN-γ is a key cytokine for the control of numerous intracellular pathogens, we analysed 
the development of E. falciformis in IFN-γ-/- and IFN-γR-/- mice. Surprisingly, significantly 
fewer parasites developed in IFN-γR-/- mice compared to wt mice, as indicated by a reduced 
number of shed oocysts (Fig. 10A, -78 %, p≤0.01). Unexpectedly, infection of IFN-γ-/- mice 
did not result in the same pattern, as there was no significant difference in the number of shed 
oocysts compared to wt mice (Fig. 10B). As described above (Fig. 9A, C), IFN-γR-/- mice 
developed severe pathology, which was associated with hemorrhagic diarrhea. To confirm the 
reliability of the quantification of shed oocysts as an adequate parameter, we assessed the 
parasite development directly at the site of infection at an early time point. In line with the 
oocyst data, analysis of caecal thin sections on d 5 p. i. revealed 86 % (p≤0.01) fewer 
parasites in IFN-γR-/- mice compared to wt mice (Fig 10C). 
As a primary infection with a dose of 50 E. falciformis oocysts followed by a secondary 
challenge infection with the same dose led to 100% mortality in IFN-γR-/- and IFN-γ-/- mice 
we instead infected mice with a primary dose of 10 oocysts and challenged them with 50 
oocysts in order to assess whether signalling via the IFN-γR is required for the development 
of immunity. Quantification of shed parasites revealed a comparable reduction of oocyst 
shedding in both IFN-γR-/- and wt mice receiving a challenge infection in comparison to 
primary infected control mice (Fig. 10A, 55% vs. 58%, p≤0.01). Oocyst production during 
challenge infection could not be assessed in IFN-γ-/- mice, as even after a primary dose of 10 
oocyst followed by a challenge infection with 50 oocysts, mice showed severe clinical signs 
and mortality making reliable quantification of oocyst impossible (data not shown). These 
results demonstrate that IFN-γR signalling is dispensable for the control of parasite replication 








Fig. 10. Pathology and parasite development in wt and IFN-γR-/- mice infected with Eimeria falciformis. 
(A) Quantification of shed oocysts from wt (circles) and IFN-γR-/- (triangles) mice following primary (1st, open 
symbols) or challenge (2nd, closed symbols) infections with 50 E. falciformis oocysts. (B) Quantification of shed 
oocysts from wt (circles) and IFN-γ-/- (triangles) mice following primary E. falciformis infection. (C) 
Quantification of asexual development (schizogony, d 5 p. i.) of E. falciformis in caecal crypts of wt (shaded 
bars) and IFN-γR-/- (open bars) mice during primary infection with 50 E. falciformis oocysts. Arrowheads point 
towards mature schizonts. Bar = 20 µm. HPF = High Power Field, 400x magnification. Data shown are mean ± 
SEM of 6-8 mice per group and representative of 4 (IFN-γR-/-) and 2 (IFN-γ-/-) independent experiments. n.s. not 
significant, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. 
 
3.1.3. Deficiency in IFN-γ  signalling leads to an expansion of IL-17A and IL-22 
producing Th17 cells 
Signalling via the IFN-γR has the ability to limit effector T cell responses and can 
reciprocally regulate other arms of the adaptive immune system by multiple mechanisms, 
thereby preventing immunopathology that would be caused by an overactive immune 
response (116). As enhanced proliferation of draining lymph node cells was seen following E. 




phenotype of the enhanced immune response in the draining lymph nodes 10 days post 
primary E. falciformis infection. Strikingly, IFN-γR-/- mice had higher amounts of IL-17A 
(8.9 ± 1.0 ng/ml vs. not detected) and IL-22 (0.43 ± 0.08 ng/ml vs. 0.05 ± 0.02 ng/ml) in the 
culture supernatants of mesenteric lymph node cells (MLNC) as compared to E. falciformis-
infected wt controls (Fig. 11A). Concomitant with the increase in Th17 cytokines, IFN-γ 
levels were strongly increased in IFN-γR-/- mice (59.4 ± 7.8 ng/ml vs. 7.2 ± 3.9 ng/ml) 
(p≤0.01, Fig. 11A). Infection of IFN-γ-/- mice resulted in a similar picture with levels of IL-
17A (51.2 ± 1.23 ng/ml vs. 1.54 ± 0.17 ng/ml) and IL-22 (0.27 ± 0.03 ng/ml vs. 0.1 ± 0.01 




Fig. 11. Production of IL-17A, IL-22 and IFN-γ in wt, IFN-γR-/- and IFN-γ-/- mice. Shown are cytokine 
concentrations in the supernatants of Eimeria falciformis-antigen-restimulated MLNC from (A) wt (shaded bars) 
and IFN-γR-/- (open bars) mice and (B) wt (shaded bars) and IFN-γ-/- (open bars) mice isolated on day 10 post 
infection with E. falciformis. Data are shown as mean ± SEM representative of 3 (A) and 2 (B) independent 
experiments with 6 to 8 mice per group. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. n.d. not detectable. 
 
Next, we determined the cellular sources of IFN-γ, IL-17A and IL-22 via flow cytometry. In 
line with the cytokine data measured by ELISA (Fig. 11) only little numbers of IL-17 and IL-
22 producing CD4+, CD8+ and CD49b+ cells were present in wt mice. The drastic increase in 
the production of IL-17A and IL-22 observed in IFN-γR-/- and IFN-γ-/- mice was almost 




our group (12), the major cellular source of IFN-γ during E. falciformis infection of wt mice 
was found to be CD8+ T cells, with smaller numbers of IFN-γ+ CD49b+ NK cells and 
relatively few CD4+ T cells (Fig. 12). Surprisingly, the enhanced IFN-γ production observed 
in culture supernatants of cells from IFN-γR-/- mice was found to be almost entirely derived 
from an increase in CD4+ IFN-γ-producing T cells (MLN, IFN-γR-/- vs. wt, 0.36 ± 0.05 x 106 
vs. 0.08 ± 0.01 x 106, p≤0.01, Fig. 12A). CD4+ IFN-γ+ T cells co-expressed T-bet (Fig. 13C), 




Fig. 12. Cellular sources of IL-17A, IL-22 and IFN-γ in wt, IFN-γR-/- and IFN-γ-/- mice. Total cell numbers 
of IL-17A-, IL-22- and IFN-γ-producing CD4+, CD8+ and CD49b+ MLNC of (A) wt (shaded bars) and IFN-γR-/- 
(open bars) mice or (B) wt (shaded bars) and IFN-γ-/-  (open bars) mice. All cells were isolated 10 days after 
primary infection with 50 E. falciformis oocysts. Data are shown as mean ± SEM representative of 3 (A) and 2 
(B) independent experiments with 6 to 8 mice per group, respectively. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. 
 
Detailed analysis of IL-17A and IL-22 producing CD4+ T cells from mesenteric lymph nodes 
(MLN) and lamina propria lymphocytes (LPL) of E. falciformis-infected IFN-γR-/- mice 
revealed a strong increase in frequencies and absolute numbers of IL-17A (10 fold increase) 
and IL-22 (6.8-fold increase) producers compared to wt mice (Fig. 13A and 13B). Analysis of 
cells of the lamina propria isolated from the E. falciformis infected caecum and proximal 
colon also showed a significant increase in the total numbers of IL-17A (12.4-fold) and IL-22 




13B). IL-17A+ MLN T cells were also found to express the master transcription factor 
retinoic acid receptor-related orphan receptor γ (RORγt), indicating these cells represent 




Fig. 13. Expansion of IL-17A and IL-22 producing Th17 cells in IFN-γR-/- mice infected with Eimeria 
falciformis. (A) Frequencies of IL-17A, IL-22 and IFN-γ positive CD4+ T cells in the MLN and (B) total cell 
numbers of IL-17A, IL-22 and IFN-γ positive CD4+ cells in the MLN and LPL of wt (shaded bars) and IFN-γR-/- 
(open bars) mice 10 days after primary infection with E. falciformis. (C) Co-expression of IL-17A/RORγt and 
IFN-γ/T-bet in the MLNC of E. falciformis infected IFN-γR-/- mice. Data shown are mean ± SEM of 4-6 mice 





A significant increase in MLN CD4+ T cell-derived IL-17A and IL-22 was also detected 
following infection of IFNγ-/- mice. Higher frequencies and a 8.9-fold increase in the total 
number of IL-17A, and 7.8-fold increase in the total number of IL-22-producing MLN CD4+ 
T cells detected in IFNγ-/- mice in comparison to wt mice further emphasise the importance of 




Fig. 14. Expansion of IL-17A- and IL-22-producing CD4+ MLN T cells in IFN-γ-/- mice infected with 
Eimeria falciformis. (A) Frequencies and (B) total cell numbers of IL-22- and IL-17A-producing CD4+ T cells 
in MLNC of wt (shaded bars) and IFN-γ-/- (open bars) mice at day 10 post infection with E. falciformis. Data 
shown are mean ± SEM of 6-8 mice per group representative of 2 independent experiments. * p ≤ 0.05, ** p ≤ 
0.01, *** p ≤ 0.001. 
 
Interestingly, we noted a subset of T cells that co-expressed both IL-17A and IFN-γ in the 
MLN and LPL of IFNγR-/- mice (Fig. 13A). These cells were found to co-express both Th1 
(T-bet)- and Th17 (RORγt)-associated transcription factors (Fig. 15), indicating the presence 







Fig. 15. Expression of T-bet and/or RORγt in IFN-γ/IL-17A producing subsets in the MLNCs of IFN-γR-/- 
mice. All cells were isolated 10 days after primary infection with 50 E. falciformis oocysts. Data are shown as 
mean ± SEM representative 2 independent experiments with 6 to 8 mice per group, respectively. * p ≤ 0.05, ** p 
≤ 0.01, *** p ≤ 0.001. 
 
Further analysis of lamina propria cells isolated from the E. falciformis-infected caecum and 
proximal colon revealed a significant increase in the total numbers of infiltrating CD4+ T cells 
in the tissue of IFN-γR-/- mice (Fig. 16A). Strikingly, the number of Gr1+ cells was increased 
by 3.8-fold in the LPL compartment in IFN-γR-/- mice (0.15 ± 0.03 x 106 vs 0.04 ± 0.01 x 106, 
p≤0.01, Fig. 16B and 16C), indicating a strong neutrophil influx, an effect commonly 
associated with Th17 responses. Conversely, although a 17-fold increase in the total number 
of Ly6C+ (Gr-1-) inflammatory monocytes in the LPL was seen following infection of wt 
mice (infected: 0.51 ± 0.01 x 106 vs. naïve: 0.03 ± 0.02 x 106) this was reduced in infected 
IFN-γR-/- mice (0.25 ± 0.04 x 106, p≤0.01), suggesting the monocyte influx was IFN-γ 
dependent (Fig. 16B and 16C). Forkhead box P3-positive (FoxP3+) regulatory T cells are 
important regulators of inflammation and tissue homeostasis. Interestingly, the number of 
CD4+ Foxp3+ cells in the LPLs was found to be significantly decreased in IFN-γR-/- mice 
compared to wt mice, suggesting the observed increase in the Th17 response may also 
inversely correlate with Treg frequencies (Fig. 16D, wt: 0.21 ± 0.02 x 106, IFN-γR-/-: 0.14 ± 








Fig. 16. Analysis of lamina propria cells in IFN-γR-/- mice infected with Eimeria falciformis. Total cell 
numbers of CD4+ T cells (A), frequencies (B) and total numbers (C) of LPL Ly-6C+ (Gr-1-) monocytes and Gr-
1+ neutrophils and total numbers of FoxP3+ cells (D) obtained from LPL cells of wt (shaded bars) IFN-γR-/- 
(open bars) mice isolated 10 days after primary infection with 50 E. falciformis oocysts. Data shown are mean ± 
SEM of 4-6 mice per group and representative of 3 independent experiments. n.s.: not significant, * p ≤ 0.05, ** 
p ≤ 0.01, *** p ≤ 0.001. 
 
3.1.4. The expression profile in the infected caecum of IFN-γR-/- mice reflects the 
dominant Th17 response  
As expected, analysis of the expression profile of downstream effector genes in the caecum 
tissue of wt mice infected with E. falciformis revealed a strong increase in Th1-associated 
genes. The mRNA encoding for CXCL9 and CXCL10, two chemokines that are important for 
migration and function of Th1 cells, and for the inducible nitric oxide synthetase (iNOS) - a 
major downstream effector of IFN-γ - were strongly induced in wt mice compared to naive 
mice (Cxcl9: 90-fold, Cxcl10: 17-fold, Nos2: 107-fold). This effect was almost completely 




comparison to naive mice (Cxcl9: 0.9-fold, Cxcl10: 0.6-fold, Nos2: 18-fold, Fig. 17A). The 
mRNA coding for the IL-23R was significantly upregulated in IFN-γR-/- mice compared to wt 
mice (6-fold, p≤0.05, Fig. 17B), whereas the levels of transcripts that are important for 
commitment of cells to the Th17 lineage, including Il6, Tgfb1 and Il23a did not differ in the 
caecal tissue of wt and IFN-γR-/- mice. Furthermore, the dominant Th17 response observed in 
IFN-γR-/- mice was also reflected by a dramatic upregulation of the transcripts encoding two 
IL-22-dependent antimicrobial peptides – regenerating islet derived proteins β and γ (RegIIIβ 
and RegIIIγ, Reg3b: 2976 fold; Reg3g: 663 fold, p≤0.01, Fig. 17C). The expression of matrix 
metalloproteinase 9 (MMP9) was also significantly increased in IFN-γR-/- mice (13-fold, 




Fig. 17. Expression profile of Th1/Th17 associated genes in the caecum of E. falciformis infected wt and 
IFN-γR-/- mice. (A) Th1 regulated genes, (B) Th17 commitment-associated genes and (C) Th17 cytokine 
regulated genes were assessed by quantitative real time PCR in the caecum of E.falciformis infected wt (shaded 
bars) and IFN-γR-/- mice (open bars) 10 days post infection. All values were normalised to expression of beta-
actin (house keeping gene) and to naïve control mice using the 2-ΔΔCt method. Data shown are mean ± SEM of 5-6 




3.1.5. IL-17A, IL-22 and IFN-γ  inhibit parasite development in vitro 
The correlation between increased levels of IL-17A and IL-22 and decreased parasite 
development observed during infections of IFN-γR-/- mice indicated a possible anti-parasite 
role of IL-17A and/or IL-22 against E. falciformis. To test this hypothesis, the mouse 
intestinal epithelial cell line CMT-93 was treated with IL-17A, IL-22, IFN-γ and IL-10 and 
the development of the parasite was assessed in vitro (in cooperation with Lara Zajic). The 
cell line was found to be immunocompetent, as demonstrated by the expression of the 
relevant cytokine receptors (Fig. 18A). E. falciformis sporozoites invaded these cells 
efficiently and developed into the first asexual generation of their life cycle (schizonts, Fig. 
18B). Invasion of CMT-93 cells by E. falciformis was unaffected by treatment with any of the 
cytokines (Fig. 18C), whereas IL-17A, IL-22 and IFN-γ all reduced the development of E. 
falciformis to the first asexual parasite generation (Fig. 18D). IL-22 and IL-17A significantly 
reduced the number of mature schizonts by 49 % (p≤0.001) and 44 % (p≤0.01), respectively, 
whereas the Th1 cytokine IFN-γ inhibited the development to a lesser extent (32 %, p<0.01). 
In contrast, treatment with IL-10 had no significant inhibitory effect on development of E. 
falciformis in this intestinal epithelial cell line. In a single subsequent experiment, 
simultaneous treatment with IL-17A and IL-22 did not further increase the inhibition of 
development of E. falciformis in CMT-93 cells, suggesting redundant functions of IL-17 and 







Fig. 18. In vitro development of Eimeria falciformis in cytokine pre-treated CMT-93 cells. (A) Expression of 
Th1/Th17 associated cytokine receptor chains in untreated CMT-93 cells detected by RT-PCR. (B) 
Representative pictures of intracellular sporozoites (4 h p. i., left panel) and a mature schizont (39 h p. i., right 
panel) in E. falciformis-infected CMT-93 cells (parasites indicated by arrow heads). (C) Invasion of E. 
falciformis in CMT-93 cells that were pre-treated for 8 h with either media alone or supplemented with 50 ng/ml 
IL-17A, IL-22, IFN-γ and IL-10 prior to infection. (D) Development (schizogony) of E. falciformis parasites 
assessed at 39 h post infection of CMT-93 cells that were pre-treated for 8 h with either media alone or 
supplemented with 50 ng/ml IL-17A, IL-22, IFN-γ and IL-10 prior to infection. The figure represents pooled 
data from 3 independent experiments that are shown as mean ± SEM of 7 to 11 samples per group. n.s.: not 
significant, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. 
 
3.1.6. A possible role for antimicrobial peptides in the limitation of parasite replication 
Antimicrobial peptides (AMPs) have been shown to be involved in host defence against 
bacteria, fungi, viruses and also parasites. Several AMPs including RegIIIβ, 
RegIIIγ, mouse β-defensin 3 (Defb3) and mouse β-defensin 4 (Defb4) are induced by IL-17 
and/or IL-22 (43). To address a possible role of these AMPs in the enhanced parasite control 
observed in IFN-γR-/- mice, we analysed transcript levels of RegIIIβ, RegIIIγ, Defb3 




vitro infection with E. falciformis in comparison to an untreated control. Furthermore, 
expression of these AMPs was also assessed in caecum tissue of E. falciformis infected IFN-
γR-/- and wt mice. Strikingly, expression of the two IL-22-dependent antimicrobial peptides 
RegIIIβ and RegIIIγ was dramatically increased in IFN-γR-/- mice compared to wt mice (Fig. 
17C). However, Reg3b and Reg3g transcripts were not detectable in CMT-93 cells in vitro 
(data not shown). Interestingly, the expression of Defb3 was upregulated 3.3-fold after 
treatment of CMT-93 cells with IL-17A (Fig. 19A). This upregulation correlated with the 
inhibition of parasite development in this epithelial cell line (Fig. 18D). However, the 
transcripts for Defb3 were not detectable in whole caecum tissue of E. falciformis-infected 
IFN-γR-/- and wt mice (Fig. 19B). Expression of Defb4 was only slightly increased after 
treatment of CMT-93 cells with IL-17A or IL-22 and similarly a 3.5-fold increase (not 
significant) in Defb4 transcript levels was detected in whole caecum tissue of E. falciformis 
infected IFN-γR-/- mice (Fig 19A and 19B). Interestingly, infection of cells treated with IL-
17A or IL-22 seemed to partly reverse the increase in Defb4 expression. Furthermore, 







Fig. 19. Expression of β-defensins in the caecum of Eimeria falciformis-infected wt and IFN-γR-/- mice and 
in infected CMT-93 cells in vitro. Expression of mouse β-defensin 3 (Defb3) and mouse β-defensin 4 (Defb4) 
in CMT-93 cells that were pre-treated with either media alone or with IL-17A, IL-22, IFN-γ and IL-10 prior to 
infection (A) or in the caecum of E.falciformis-infected wt and IFN-γR-/- mice 10 days post infection (B) was 
assessed by quantitative real time PCR. All values were normalised to expression of beta-actin (house keeping 
gene) and to naïve control mice using the 2-ΔΔCt method. Data shown are mean ± SEM of 5-6 mice per group and 





3.1.7. IL-17A and IL-22 partially mediate immunopathology and IL-22 has anti-
parasitic effects during E. falciformis infection  
To further dissect the roles of IL-17A and IL-22 in our model in vivo, we concurrently 
depleted IL-17A and IL-22 during infections of wt and IFN-γR-/- mice with E. falciformis. 
Simultaneous neutralisation of IL-17A and IL-22 significantly reduced the E. falciformis-
induced body weight loss in IFN-γR-/- mice, whereas antibody neutralisation had no 
significant effects on body weight loss in wt treated mice in comparison to control-IgG treated 
mice (Fig. 20A).  Furthermore, combined neutralisation of IL-17A and IL-22 led to a 
reduction in E. falciformis-induced histological changes as indicated by an almost normal 
intestinal architecture (Fig. 20B). IL-17A/IL-22 neutralisation correlated with a significantly 
lower inflammation as indicated by a reduction in the total number of infiltrating CD4+ T 
cells and Gr-1+ neutrophils in the lamina propria of E. falciformis-infected IFN-γR-/- mice 
following antibody treatment (p≤0.05, Fig. 20C). As well as drastically reducing infection-
induced pathology, concurrent neutralisation of IL-17A and IL-22 led to significantly higher 
numbers of shed oocysts in comparison to IgG treated IFN-γR-/- controls (anti-IL-17/IL-22: 
0.23 ± 0.02 x 106 vs. IgG: 0.13 ± 0.01 x 106, p≤0.01, Fig. 20D). The increased oocyst 
shedding was further found to correlate with significantly reduced expression of the IL-22-
dependent antimicrobial peptides RegIIIβ and RegIIIγ in the intestinal tissue of infected mice 







Fig. 20. Concurrent neutralisation of IL-17A and IL-22 during E. falciformis infection of wt and IFN-γR-/- 
mice. (A) Body weight loss of wt (circles) and IFN-γR-/- (triangles) mice infected with 50 E. falciformis oocysts 
and treated with 200 µg anti-IL17A and anti-IL-22 antibodies (green) each at days -1, 2, 5 and 8 p. i. Control 
groups (black) received a mouse IgG antibody. Mice were euthanised upon 20 % body weight loss (dotted line). 
(B) Representative pictures of H & E stained caecal thin sections. Bar = 100µm. (C) Total cell numbers of LPL 
CD4+ T cells and Gr-1+ cells in wt (shaded bars) and IFN-γR-/- (open bars) mice following concurrent anti-IL-
17A/anti-IL-22 treatment. (D) Quantification of shed oocysts from d 8 to 10 p. i. of wt (circles) and IFN-γR-/- 
(triangles) mice infected with 50 E. falciformis oocysts and treated with anti-IL17A and anti-IL-22 antibodies 
(green) or a control IgG antibody (black). (E) Expression of the antimicrobial peptides RegIIIβ and RegIIIγ in 
caecum samples of wt (shaded bars) and IFN-γR-/- (open bars) mice after infection with 50 E. falciformis 
oocysts. Values normalised to ß-actin (house keeping gene) and depicted as relative expression compared to 
naïve control mice using the 2-ΔΔCt method. Data shown are mean ± SEM of 4-8 mice per group representative of 




In contrast, single neutralisation of either IL-17A or IL-22 failed to significantly reverse E. 
falciformis induced body weight loss in IFN-γR-/- mice, suggesting these cytokines may have 
redundant roles in driving immunopathology during E. falciformis infection (Fig. 21A and 
21B). In comparison, whereas neutralisation of IL-17A alone had no significant effect on 
oocyst output in E. falciformis infected mice (Fig. 21A), single neutralisation of IL-22 led to a 
significant increase in oocyst shedding in IFN-γR-/- mice in comparison to controls (Fig. 21B). 
The increase in oocyst shedding following IL-22 single neutralisation was comparable to the 
effect seen in IL-17A/IL-22 double neutralised mice, suggesting that IL-22 was the dominant 




Fig. 21. Neutralisation of IL-22 or IL-17A during Eimeria falciformis infection. (A) Body weight loss and 
quantification of shed oocysts from d 8 to 10 p. i. of wt (circles) and IFN-γR-/- (triangles) mice infected with 50 
E. falciformis oocysts and treated with 200 µg anti-IL17A antibody (A) or anti-IL-22 antibody (B) (green) each 
at days -1, 2, 5 and 8 p. i. Control groups received a mouse IgG antibody (black). Mice were euthanised upon 20 
% body weight loss (dotted line). Data shown are mean ± SEM of 5-8 mice per group representative of 2 





3.1.8. Inducible nitric oxide synthetase (iNOS) is not involved in host defence but limits 
pathology in infections with E. falciformis 
iNOS catalyses the production of the free radical NO which leads to subsequent formation of 
reactive nitrogen intermediates that have important functions in the immune defence against 
intracellular pathogens at epithelial sites. Signalling via the IFN-γR is one of the major 
pathways for the induction of iNOS (16). To analyse the role of this immune mediator 
downstream of IFN-γ in infections with E. falciformis, we compared body weight loss and 
parasite development in mice deficient in this enzyme (iNOS-/-) and in wt mice. Interestingly, 
iNOS-/- mice showed severe body weight loss similar to infections of IFN-γR-/- and IFN-γ-/- 
mice (Fig. 22A and Fig. 9A-C). There was no significant difference in the number of shed 
oocysts after infection with E. falciformis (Fig. 22B). Challenge infection of the mice 
demonstrated an unimpaired development of immunity as oocyst shedding was reduced to a 
similar extent in both mouse strains compared to a primary infection control group (iNOS-/-: -
71% wt: -95% Fig. 22C). Thus, the production of reactive oxygen intermediates via iNOS is 
not involved in the limitation of E. falciformis development and also does not interfere with 
the development of immunity against challenge infections. However, the results indicate an 





Fig. 22. Body weight loss and parasite development in wt and iNOS-/- mice infected with Eimeria 
falciformis. (A) Body weight loss of wt (circles) and iNOS-/- (triangles) mice after primary (1st, open symbols) 
and challenge (2nd, closed symbols) infections with 50 E. falciformis oocysts. (B) Quantification of shed oocysts 
from wt (circles) and IFN-γ-/- (triangles) mice following primary E. falciformis infection. (C) Quantification of 
shed oocysts from wt (circles) and IFN-γR-/- (triangles) mice following primary (1st, open symbols) or secondary 
(2nd, closed symbols) E. falciformis infection. Data shown are mean ± SEM of 5-8 mice per group and 
representative of 2 (A) independent experiments or shown as pooled data from 4 (B) and 2 (C) independent 





Next, we assessed the production of IL-17A and IL-22 by CD4+ MLN cells isolated from 
iNOS-/- mice and wt mice 10 days post E. falciformis infection via flow cytometry. We 
observed an increase in frequencies of IL-17A- and IL-22-producing CD4+ T cells of iNOS-/- 
mice in comparison to wt mice (Fig. 23A) Furthermore, absolute cell numbers were increased 
4.6-fold (IL-17A) and 2.5-fold (IL-22) in iNOS-/- mice compared to wt mice (Fig. 23B, p ≤ 
0.05). However, the increase in IL-17A- and IL-22-producing CD4+ MLN cells was much 
weaker than in IFN-γR-/- and IFN-γ-/- mice (Fig. 13 and Fig. 14). There was no significant 




Fig. 23. Expansion of IL-17A- and IL-22-producing CD4+ MLN T cells in iNOS-/- mice infected with 
Eimeria falciformis. (A) Frequencies and (B) total cell numbers of IL-22 and IL-17A producing CD4+ T cells in 
MLNC of wt (shaded bars) and iNOS-/- (open bars) mice at day 10 post infection with E. falciformis. Data shown 
are mean ± SEM of 6-8 mice per group representative of 2 independent experiments. * p ≤ 0.05, ** p ≤ 0.01, *** 





3.2. Establishment of a transfection system for E. falciformis 
3.2.1. Pyrimethamine as a selection marker for transgenic parasites 
Pyrimethamine is a drug that has been commonly used for treatment of Malaria and – in 
combination with sulfadiazine – is used to treat infections with T. gondii in 
immunocompromised individuals. Pyrimethamine inhibits the enzyme complex dihydrofolate 
reductase thymidilate synthetase (DHFR-TS), which catalyses the synthesis of tetrahydrofolic 
acid from folic acid. A functional folate metabolism is essential for DNA synthesis of many 
organisms, including apicomplexan parasites. A mutated version of T. gondii DHFR-TS that 
is insensitive to pyrimethamine has been widely used as a selection marker for transfected 
parasites, including Eimeria tenella (82, 117). To test the suitability of pyrimethamine as a 
selection marker for transgenic E. falciformis parasites, we assessed the killing of wild type E. 
falciformis with pyrimethamine that was applied via different routes and in several 
formulations. 
 
3.2.1.1. Application in drinking water 
Administration of pyrimethamine dissolved in dimethyl sulfoxid (DMSO) and diluted in 
acidified tape water is the standard protocol used for selection of Plasmodium spp. However, 
pyrimethamine applied via the drinking water in concentrations of 1 and 2 mg/kg did not 
reduce the number of shed oocysts in comparison to an untreated control (Fig. 24A). 
 
3.2.1.2. Application via oral gavage 
In a subsequent experiment, pyrimethamine (1 mg/kg and 2 mg/kg) was administered to mice 
via oral gavage from d 1 to d 6 p. i. As described above for application in the drinking water, 
the drug had no effect on the number of shed parasites at concentrations up to 2 mg/kg (data 
not shown). Next, we prepared an emulsion of pyrimethamine in Cremophor EL®. Treatment 
of mice with 20 mg/kg pyrimethamine from d 1 to 6 p. i. led to a reduction in shed oocysts by 
41 % (Fig. 24B, not significant). Increasing the dose to 40 and 80 mg/kg did not result in 
better inhibition of parasite development. Furthermore, the high viscosity of Cremophor 
caused severe problems in the administration using oral gavage. To circumvent these 




formulation 40 mg/kg pyrimethamine reduced the number of shed oocysts by 93 %. Inhibition 
of parasite development could be increased to 98 %, when a dose of 80 mg/kg pyrimethamine 
was used (Fig. 24C). To further improve killing of wild type parasites, pyrimethamine was 
dissolved in a 2:1 mixture of DMSO and polyethylene glycol 400 (PEG 400) and 80 mg/kg 
were administered to mice from d 1 to 6 p. i. This almost completely abrogated replication of 
E. falciformis, with the number of shed oocysts being reduced by 99.9 % (Fig. 24D). 
Treatment with higher doses of pyrimethamine was not possible, as the LD50 for oral 




Fig. 24. Replication of Eimeria falciformis in mice treated orally with pyrimethamine. Shown is the number 
of oocysts shed by NMRI mice on d 8 to 10 post infection with E. falciformis after oral treatment with 
pyrimethamine from d 1 to 6 p. i. (A) Pyrimethamine dissolved in DMSO and suspended in acidified drinking 
water. (B) Pyrimethamine emulsified in Cremophor EL and applied via oral gavage. (C) Pyrimethamine ground 
up, suspended in water and applied via oral gavage. (D) Pyrimethamine dissolved in a 2:1 mixture of DMSO and 
PEG400 and applied via oral gavage. Data shown are mean ± SEM of 3-4 mice per group representative of 2 (A, 
B) and 3 (C, D) independent experiments. 
 
3.2.1.3. Intraperitoneal application 
To address the question, if intraperitoneal (i. p.) application can improve killing of E. 
falciformis, pyrimethamine was dissolved in ethanol and 5 mg/kg were injected i. p. on days 1 
to 6 p. i. into mice. However, compared to a control group that received the solvent only, no 
reduction in the number of shed oocysts could be observed (Fig. 25A). In a second 
experiment, doses of 20 and 30 mg/kg pyrimethamine were used for treatment. The drug was 
dissolved in a 2:1 mixture of DMSO and PEG400, as the solubility is higher than in ethanol. I. 
p. treatment with 20 mg/kg pyrimethamine from d 1 to 6 p. i. reduced the number of shed 




with an equivalent oral dose of pyrimethamine (- 65 %, Fig. 26B). All mice succumbed to 




Fig. 26. Replication of Eimeria falciformis in mice treated intraperitoneally with pyrimethamine. Shown 
are body weight loss and number of oocysts shed by NMRI mice on d 8 to 10 post infection with E. falciformis 
after treatment with pyrimethamine from d 1 to 6 p. i. (A) Pyrimethamine dissolved in ethanol and injected i. p. 
(B) Pyrimethamine dissolved in a 2:1 mixture of DMSO and PEG400 and injected i. p. or applied via oral 
gavage. Data shown are mean ± SEM of 3-5 mice per group representative of 2 independent experiments. 
 
3.2.1.4. Application in diet 
Food containing pyrimethamine in concentrations of 200, 400 and 600 parts per million (ppm) 
was provided to the mice ad libitum 18 hours p. i. until day 6 p. i. 200 ppm dietary 
pyrimethamine reduced the number of shed oocysts by 63 % compared to an untreated control 
group. Increasing the pyrimethamine concentration to 400 ppm did further reduce oocyst 
shedding (-87 %), while treatment with 600 ppm dietary pyrimethamine had no additional 
inhibitory effect (-82 %, Fig. 27A). The latter effect could be explained by the actual effective 




the untreated control group consumed approximately 4.4 g food per day, this amount 
decreased with increasing concentration of pyrimethamine in the diet (200 ppm: 3.9 g, 
400ppm: 3.4 g, 600 ppm: 2.8 g, Fig. 27B). Given an average weight of 30 g of a NMRI mouse 
at day 0, the resulting mean dose of pyrimethamine was 27 mg/kg (200 ppm diet), 45 mg/kg 
(400 ppm diet) and 54 mg/kg (600 ppm diet). In correlation with decreased food consumption 
treatment with pyrimethamine led to a dose dependent increase in body weight loss (Fig. 
27C). Whereas no weight loss was measured in the untreated control group at day 10 p. i., 
mice receiving 200 ppm had lost 9.4 % of their weight and this effect was even more severe 
among the animals receiving 400 ppm (14.6 %) and 600 ppm (19 %), respectively. Thus, 





Fig. 27. Replication of Eimeria falciformis in mice treated with dietary pyrimethamine. (A) Number of 
oocysts shed by NMRI mice on d 8 to 10 post infection with E. falciformis after dietary treatment with 200, 400 
and 600 ppm pyrimethamine from d 1 to 6 p. i. (B) Average daily food consumption of E. falciformis-infected 
mice treated with 200, 400 and 600 ppm dietary pyrimethamine. (C) Body weight loss of E. falciformis-infected 
mice treated with 200, 400 and 600 ppm dietary pyrimethamine. Data shown are mean ± SEM of 3-5 mice per 




3.2.1.5. Pyrimethamine / 2-hydroxypropyl-β-cyclodextrin inclusion complexes 
We generated inclusion complexes (PHIC) of pyrimethamine in the widely used hydrophilic 
drug carrier 2-hydroxypropyl-b-cyclodextrin. The PHIC were first tested in vitro against T. 
gondii, which is known to be sensitive to pyrimethamine at 1 µM. Consequently, 
supplementation of the cell culture medium with 1 µM pyrimethamine led to a complete 
growth inhibition of T. gondii compared to an untreated control, where large numbers of 
egressed tachyzoites could be observed after 48 h (Fig. 28A). When pyrimethamine was 
provided in inclusion complexes with 2-hydroxypropyl-β-cyclodextrin, a dose of 2 µM was 
required to achieve complete inhibition of T. gondii replication (Fig. 28A). To test the 
effectivity of PHIC against E. falciformis, 0.2 and 2 mM pyrimethamine in PHIC was 
prepared and provided to mice in drinking water. However, there was no reduction in the 
number of shed oocysts (Fig. 28B). Oral or intraperitoneal application of 250 µg 










Fig. 28. Replication of Eimeria falciformis in mice treated with inclusion complexes of pyrimethamine in 2-
hydroxypropyl-β-cyclodextrin (PHIC). (A) Egress of T. gondii tachyzoites 48 h after infection of Human 
Foreskin Fibroblast (HFF) monolayers treated with pyrimethamine supplemented in culture medium. Scale bar = 
20 µm. (B) Number of oocysts shed by NMRI mice on d 8 to 10 post infection with E. falciformis after treatment 
with 0.2 and 2 mM pyrimethamine in PHIC via drinking water from d 1 to 6 p. i. (C) Number of oocysts shed by 
NMRI mice on d 8 to 10 post infection with E. falciformis after oral / i. p. treatment with 250 µg pyrimethamine 
in PHIC (~8 mg/kg) from d 1 to 6 p. i. n = 1.  
 
3.2.2. Rectal infection of mice with E. falciformis sporozoites 
Only sporozoites purified from sporulated oocysts of E. falciformis are accessible to 
transfection and there is no system for in vitro selection of transgenic parasites. Thus, 
sporozoites have to be purified, transfected and administered to mice for in vivo selection. As 
sporozoites applied via oral gavage would be killed during passage through the acidic 
environment of the stomach, we aimed to apply sporozoites rectally to mice. However, it has 
not been shown so far, if E. falciformis sporozoites applied rectally to mice can successfully 




were infected rectally with 6.5 x 105 sporozoites, the number of parasites that we also used for 
infections of mice in subsequent transfection experiments. Rectally infected mice shed 0.41 ± 
0.11 x 107 oocysts (Fig. 29A). To assess the infectivity of parasites derived from a rectal 
infection, naïve mice were infected with the oocysts from this experiment. The number of 
shed parasites was not significantly different when compared to a control group that received 
an identical dose of oocysts from an oral passage (oral: 1.0 ±0.18 x 107, rectal: 1.43 ± 0.06 x 




Fig. 29. Rectal infection of mice with Eimeria falciformis sporozoites. (A) Number of oocysts shed by NMRI 
mice on d 8 to 10 post infection with E. falciformis after rectal infection with 6.5 x 105 sporozoites. (B) Number 
of oocysts shed by NMRI mice on d 8 to 10 post infection with E. falciformis after oral infection with oocysts 
derived from an oral (closed circles) or rectal (open circles) infection. Data shown are mean ± SEM of 3-4 mice 
per group from 1 experiment. 
 
3.2.3. Original plasmids used for transfection of E. falciformis. 
Two plasmids were used for initial transfection experiments (a gift from Fiona Tomley, IAH 
Compton, UK; Fig. 30). The first construct (pmic1YFPmact) harboured the reporter Yellow 
Fluorescent Protein (YFP) flanked by the 5’ untranslated region (UTR) and promotor of the 
E. tenella microneme protein 1 (Etmic1) gene and the E. tenella actin 3’UTR. The second 
construct (pactDHTSact) harboured a copy of the gene for the mutated, primethamine 
resistant dihydrofolate reductase-thymidin synthetase enzyme complex (DHFR-TSm2m3) 
flanked by the 5’ UTR and promoter of the E. tenella actin gene (Etact) and the 3’ UTR of 
Etact. Both plasmids were used for co-transfection of purified E. falciformis sporozoites (see 




unsporulated oocysts (see 3.2.4). Furthermore, reporter and resistance cassette from these 
original plasmids were used to design constructs for random and single homologous 




Fig. 30. Original plasmids used for transfection of E. falciformis. The construct pmic1YFPmact harboured 
the reporter YFP under the control of the E. tenella microneme protein 1 promoter. The construct pactDHTSact 
contained the resistance marker “mutated dihydrofolate reductase-thymidin synthetase enzyme complex” 
(DHFR-TSm2m3) under control of the E. tenella actin promoter. The genes are flanked by the depicted 
untranslated regions (UTR). Plasmids were a gift from Fiona Tomley, IAH Compton, UK. 
 
3.2.4. Transfection of unsporulated oocysts 
All published data on transfection of Eimeria spp. have used purified sporozoites and there 
are no data on the transfection of sporulated or unsporulated oocysts. The reason for this 
might be the two highly resistant cyst shells that protect the sporozoite from environmental 
influences. However, unsporulated oocysts contain homogenous material from which 
sporocysts and sporozoites develop and that is protected by the oocyst shell only. Thus, 
transfection of unsporulated oocysts could facilitate the incorporation of the transfected 
reporter and/or resistance cassette into the developing sporozoite. To test if transfection across 
the cyst shell is suitable, 1 x 106 freshly passaged unsporulated oocysts were purified, 
optionally treated with sodium hypochloride (NaOCl) for 15 or 30 min on ice to weaken the 
oocyst shell and electroporated with the reporter construct pmicYFPmact (see 5.2.12). 10 U 
PsiI were added for restriction enzyme mediated integration (REMI). After sporulation in 
potassium dichromate oocysts were screened microscopically for YFP expression. 
Sporulation occurred normal in all samples, but no YFP-expressing oocysts were found in any 




3.2.5. Transfection of sporozoites 
3.2.5.1. Co-transfection with reporter and resistance plasmid 
Based on published data for E. tenella (82), purified E. falciformis sporozoites were 
transfected with pmic1YFPmact and pactDHTSact in a ratio of 10:1 using the Amaxa 
Nucleofector® electroporation system (Fig. 32). Mice were infected rectally with these 
sporozoites and treated orally with 80 mg/kg pyrimethamine from d 1 to 8 p. i. Faeces of the 
peak days of oocyst shedding (d 8-10 p. i.) were collected, and oocysts were sporulated, 
purified from the faeces and screened for YFP-expression microscopically. We identified 
oocysts with 1 to 4 YFP-expressing (YFP+) sporocysts and various fluorescence intensities 





Fig. 31. YFP-expressing E. falciformis oocysts after co-transfection. (A) Oocysts were purified after the first 
in vivo passage and YFP+ oocysts were isolated manually. (B) Control. Oocysts after mock-transfection do not 
show any fluorescence. 
 
On average 0.006 ± 0.002 % of the shed oocysts expressed YFP (Fig. 32A). This corresponds 
to a mean absolute number of only 20 YFP+ oocysts per mouse. At these low percentages, 
YFP+ oocysts could not be isolated via FACS (data not shown) and thus manual selection of 
the YFP+ oocysts was performed using an inverted fluorescence microscope. For subsequent 
in vivo selection single oocysts harbouring 4 YFP+ sporocysts were administered to mice via 
oral gavage. Pyrimethamine selection was not applied in this experiment. As in the previous 
passage, oocysts were sporulated, purified and the total number of shed oocysts and the 
percentage of YFP+ oocysts were determined microscopically. However, only 0.59 ± 0.24 % 




were infected with a single oocyst that harboured 4 YFP+ sporocysts in two additional 
passages for in vivo selection. Whereas the 3rd passage led to a slight increase in the 
percentage of YFP+ oocysts (1.16 ± 0.39 %) compared to the previous passage, only 0.18 ± 




Fig. 32. Co-transfection and repeated manual selection of single oocysts with 4 YFP+ sporocysts. E. 
falciformis sporozoites were co-transfected with pmic1YFPmact and pactDHTSact. Percentage (A) and absolute 
number (B) of YFP+ oocyst after several rounds of in vivo selection. (C) Number of oocysts shed in total. Data 
are shown as mean ± SEM of 4-11 mice per group from one experiment. 
 
Thus, co-transfection and subsequent repeated manual selection of single oocysts that 
harboured 4 YFP+ sporocysts was not suitable to establish a stable transgenic population. 
However, the larger number of YFP+ oocysts obtained from the 3rd passage (11570 ± 4940, 
Fig. 32B) could be isolated for further analysis using fluorescence activated cell sorting 








Fig. 33. Sorting of YFP+ oocysts using FACS. Oocysts were purified from faeces via flotation with NaOCl, 
washed and passed through 30 µm cell strainers. Oocysts resuspended in deionised water were sorted on a FACS 
Aria (BD). Microscopic screening of the sorted populations revealed a purity of  > 99 %.  Plots are 
representative of at least 4 independent sorts. 
 
We questioned whether the introduced genes were not sufficiently expressed or deleted from 
the genome of the parasite. To test the later case, the presence of the YFP gene in genomic 
DNA of the parasite was assessed. Genomic DNA from large numbers (> 1 x 104) of YFP+ 
oocysts that had been enriched using Fluorescence Activated Cell Sorting (Fig. 33) was used 
for PCR with primers specific for the YFP gene and β-actin as an internal control. The YFP 
gene could be clearly detected in the YFP+ population, whereas it was absent from YFP- 
negative oocysts (Fig. 34). Importantly, the sorted YFP-expressing (YFP+) and YFP-negative 
(YFP-) oocyst populations were both derived from an infection with a single YFP+ oocyst (4 
YFP+ sporocysts). This shows that the reporter gene gets deleted from the major part of the 
parasites during asexual or sexual replication. These experiments do not reveal, if the 
transfected constructs are integrated into the genome or maintained as episomes. Southern 
blot analysis would answer this question. However, the amount of DNA from YFP+ oocysts 







Fig. 34. Amplification of YFP from genomic DNA of YFP+ and YFP- oocysts derived from infection with 
a single YFP+ oocyst. FACS sorted YFP+ and YFP- populations were over 99 % pure. Genomic DNA was 
extracted and the YFP gene was detected with specific primers. β-actin served as an internal control. ø = PCR 
negative control (no template). 
 
3.2.5.2. Transfection with linearised plasmids containing reporter and resistance 
marker in different orientations 
To improve the selection of transgenic parasites and to simplify the protocol for transfection, 
we designed constructs that contained reporter (YFP) and resistance marker (DHFR-TS) on 
one plasmid. Based on the original plasmids (Fig. 30) three constructs (pDHTSYFP, 
prevDHTSYFP, pDHTSrevYFP) were designed, harbouring reporter and resistance cassette 
in different orientations (Fig. 35). Furthermore, we also constructed these three plasmids with 
the red fluorescing reporter tdTomato to enable more flexibility in future imaging experiments 







Fig. 35. Plasmids with reporter and resistance marker. The constructs contain the reporter cassette with YFP 
under control of the E. tenella microneme protein 1 promoter and the resistance cassette with DHFR-TSm2m3 
under control of the E. tenella actin promoter. Reporter and resistance cassette are inserted in different 
orientations as depicted. 
 
Purified E. falciformis sporozoites were transfected with linearised plasmids using cytomix 
buffer (Fig. 36A) or Basic Parasite Nucleofector solution 1 from the Amaxa Nucleofector® 
system (Fig. 36B, programme U-033). Transfected parasites were passaged through mice 
under pyrimethamine selection and shed oocysts were screened for YFP expression. No big 
differences in the percentages of YFP+ oocysts between the constructs with different 
orientations of reporter and resistance marker were observed in the first experiment (Fig. 
36A). However, the absolute number of YFP+ oocysts was increased 10-fold for 
pDHTSrevYFP compared to the other constructs. Interestingly, transfection using the Basic 
Parasite Nucleofector solution 1 resulted in higher percentages of YFP+ oocysts in all 
samples. The difference was most prominent in parasites transfected with pDHTSrevYFP. 
Whereas 0.002 % of all oocysts expressed the fluorescent reporter after transfection using 
cytomix buffer, this percentage could be increased 13-fold (0.025 %) using the Basic Parasite 
Nucleofector solution 1 (Fig. 36A and 36B). The pDHTSrevYFP sample also contained the 
highest absolute number of YFP+ oocysts when compared to the other single plasmids. Based 
on the results from these experiments, we decided to use the newly constructed 







Fig. 36. Transfection with single plasmids harbouring reporter and resistance marker. Purified E. 
falciformis sporozoites were transfected with linearised plasmids (Fig. 35) using cytomix buffer (A) or Basic 
Parasite Nucleofector solution 1 (B). Plasmid ratio in co-transfection was 1:10 in (A) and 1:1 in B. Transfected 
parasites were passaged through mice under pyrimethamine selection. Left panels: Percentages of YFP+ oocysts 
and absolute numbers of YFP+ oocysts (values above bars). Right panels: Total number of shed oocysts from d 8 
to 10 p. i. 
 
The YFP+ oocyst population from the first in vivo selection after transfection with 
pDHTSrevYFP (Fig. 36A) was isolated using FACS, and the sorted YFP+ oocysts were 
repeatedly passaged through mice under pyrimethamine selection as shown in Fig. 37B. The 
percentage of YFP+ oocysts increased only slightly from 0.002 ± 0.00 % in the first passage 
to 0.006 ± 0.0004 % in the second passage (Fig. 37A). Due to the sharp increase in the 
number of total oocysts, the absolute number of YFP+ oocysts was multiplied 5-fold (1st 
passage: 49, 2nd passage: ø 266). This trend continued during the 3rd passage with 0.16 ± 0.01 
% YFP+ oocysts and a 2-fold increase in the number of YFP+ oocysts (565 ±120, Fig. 37A). 
To enrich oocysts that harboured 4 YFP+ sporocysts, only oocysts with high fluorescence 
intensity (YFPhigh) were sorted using FACS (Fig. 37C). Subsequently, YFP+ oocysts (4 YFP+ 




selection. However, this 4th passage did not increase the percentage or yield of YFP+ oocysts. 
Even two further passages under pyrimethamine selection did not improve the overall picture. 
The percentage of YFP+ oocysts was still low (6th passage: 0.07 ± 0.03 %) and the absolute 





Fig. 37. Transfection with linear pDHTSrevYFP and repeated in vivo selection. Sporozoites were 
transfected with linearised pDHTSrevYFP using the Basic Parasite Nucleofector Solution 1 and Amaxa 
Nucleofector II programme U-033 (sample pDHTSrevYFP from Fig. 36A). Transfected parasites were 
repeatedly passaged through mice using the selection parameters depicted in (B). (C) FACS sort of YFPhigh 





3.2.5.3. Transfection with circular pDHTSrevYFP 
We transfected sporozoites with circular pDHTSrevYFP using the Basic Parasite 
Nucleofector Solution 1 and Amaxa Nucleofector II programme U-033. Two mice were 
infected rectally with the transfected parasites and treated orally with 80 mg/kg 
pyrimethamine from d 1 to 6 p. i. After the first selection round 0.03 % (mouse 1) and 0.13 % 
(mouse 2) of all shed oocysts expressed YFP (Fig. 38A). Manual selection of 2 YFP+ oocysts 
from the 0.13 % sample and a second in vivo passage under pyrimethamine selection led to 
maximal 6.1 % YFP+ oocysts. Again, YFP+ oocysts were sorted manually from the sample 
with the highest percentage of YFP+ oocysts and passaged through mice for further 
enrichment (11 oocysts/mouse). The percentage of YFP+ oocysts increased slightly to 7.4 % 
in one sample (Fig. 38A). 70 YFP+ oocysts could be isolated using FACS and submitted to a 
fourth in vivo passage under pyrimethamine selection (2 mice). Shed oocysts from one mouse 
harboured 13.2 % YFP+ oocysts, the highest percentage observed in all experiments so far 
(Fig. 38A). Interestingly, the absolute number of YFP+ oocysts increased sharply (4th 
passage: 2.0 x 104 vs 3rd passage: 0.18 x 104, Fig. 38B).  In a subsequent experiment, 260 
YFP+ oocysts recovered from the FACS sort were passaged through two mice (130 each) 
under pyrimethamine selection. Unexpectedly, only 3.5 % of all shed oocysts expressed the 
fluorescent reporter. In contrast to the decrease in the percentage of YFP+ oocysts, their 
absolute number increased further (5th passage: 6.9 x 104 vs 4th passage: 2.00 x 104, Fig. 38B). 
As in the previous passage this was due to a sharp increase in the total number of shed oocysts 
(Fig. 38C). A 6th passage of 200 YFP+ FACS sorted oocysts under pyrimethamine selection 
did not substantially increase the percentage of fluorescent oocysts and compared to the 








Fig. 38. Transfection with circular pDHTSrevYFP and repeated in vivo selection. Sporozoites were 
transfected with circular pDHTSrevYFP using the Basic Parasite Nucleofector Solution 1 and Amaxa 
Nucleofector II programme U-033. Transfected parasites were passaged through mice under pyrimethamine 
selection (80 mg/kg via oral gavage from d 1 to 6 p. i.). Manually or FACS sorted YFP+ oocysts were repeatedly 
passaged in vivo. 
 
3.2.5.4. Alternating passage with and without pyrimethamine selection 
To identify possible integrations events, we passaged oocysts from the previous experiment 
(pDHTSrevYFP, circular, 6th passage, Fig. 38) with and without pyrimethamine selection in a 
parallel experiment. Mice were infected with a single manually selected oocyst expressing 
YFP in all 4 sporocysts. As expected, the percentage of YFP+ oocysts was higher after 
passage under selection pressure compared to passage without pyrimethamine treatment (with 
selection: 6.84 ± 1.83 %, without selection: 0.13 ± 0.06 %, Fig. 39A). Furthermore, mice that 
did not receive pyrimethamine shed more oocysts than treated mice (with selection: 0.12 ± 
0.07 x 105, without selection: 1.0 ± 0.4 x 105, Fig. 39A). Interestingly and despite a low 
percentage of YFP+ oocysts, this resulted in a relatively high number (660) of fluorescent 
reporter expressing oocysts in one sample of the untreated group (Fig. 39A, arrow). YFP+ 
oocysts from this sample were isolated manually and mice were infected with 1 oocyst (4 
YFP+ sporocysts) for an additional passage with and without pyrimethamine selection. After 
passage under selection the percentage of YFP+ oocysts increased again, with one sample 
harbouring 6.4 % fluorescent parasites (Fig. 39B). Interestingly, the percentage of YFP+ 
oocysts in the untreated group did not decrease compared to the previous passage (previous 
passage: 0.13 ± 0.06 %, this passage: 0.2 ± 0.06 %). Surprisingly, the total numbers of shed 
oocysts were very low in both groups (Fig. 39B). For the next round of selection mice were 
infected with 1000 oocysts from the sample with the highest percentage of YFP+ oocysts and 




this passage harboured 34.9 % YFP+ oocysts, but the low number of total oocysts shed 




Fig. 39. Repeated in vivo selection of oocysts transfected with circular pDHTSrevYFP. Passage of a single 
oocyst harbouring 4 YFP+ sporocysts through mice under pyrimethamine treatment or without selection (A and 
B). YFP+ oocysts from the sample marked with an arrow in (A) were used for infection of mice for the passage 
displayed in (B). Likewise 1000 oocysts from the marked sample in (B) were used for infection of mice shown 





3.2.5.5. Influence of plasmid concentration on the transfection efficiency 
Based on published data for E. tenella, 1012 plasmid molecules have been used for 
transfection of E. falciformis (82). To test, whether introduction of higher DNA amounts 
increases transfection efficiency, sporozoites were transfected with 22 (=1012 molecules), 50 
and 200 µg circular pDHTSrevYFP, respectively in 100 µl Basic Parasite Nucleofector 
Solution 1 using the Amaxa Nucleofector II programme U-033. Transfected parasites were 
passaged through mice under pyrimethamine selection. From all shed oocysts 0.02 ± 0.01 % 
(22 µg), 0.003 ± 0.001 (50 µg) and 0.08 ± 0.04 (200 µg) expressed YFP (Fig. 40A). The 
numbers of YFP+ oocysts being highly variable, higher plasmid concentrations did not result 
in considerably higher transfection rates (Fig. 40B). On average, a 10-fold higher plasmid 




Fig. 40. Influence of plasmid concentration on the transfection efficiency. Sporozoites were transfected with 
22 µg (=1012 molecules), 50 µg or 200 µg circular pDHTSrevYFP in 100 µl Basic Parasite Nucleofector 
Solution 1 using the Amaxa Nucleofector II programme U-033. Transfected parasites were passaged through 
mice under pyrimethamine selection. Shown are percentage (A) and absolute numbers (B) of YFP+ oocysts, as 
well as the total number of shed oocysts (C). 
 
3.2.5.6. Transfection with the linearised fusion construct pactDHTSlinkYFPact 
To circumvent the possible problem that the reporter cassette gets deleted from the parasite, 
while the resistance cassette is maintained, we used a plasmid, harbouring the YFP and DHTS 
gene under the control of a single E. tenella actin promotor (a gift from M. Kurth, TU 
Dresden, Fig. 41A). Purified E. falciformis sporozoites were transfected with 1012 linearised 
molecules of pactDHTSlinkYFPact using the Basic Parasite Nucleofector Solution 1 in 




pyrimethamine from d 1 to 6 p. i. Oocysts collected from d 8 to 10 p. i. were purified and 
screened microscopically for YFP expression. One mouse shed 2 x 104 oocysts from which 91 
were found to express YFP (0.46 %, Fig. 41B). Interestingly, most of the YFP+ oocysts 
harboured 4 YFP+ sporocysts. However, only 0.03 % (4/15000) of the oocysts from a second 
mouse were YFP+. 30 oocysts were isolated manually from the first sample (0.46 %) and 3 
mice were infected with 10 YFP+ oocysts each for a second in vivo passage under 
pyrimethamine selection. The percentage of YFP+ oocysts did not increase during this 
passage, as only 0.34 ± 0.12 of all shed oocysts were found to express YFP. Similar to the 
experiments with other constructs, the total number of shed oocysts and thus also the total 





Fig. 41. Transfection with the linearised fusion construct pactDHTSlinkYFPact. (A) Fusion construct. 
DHFR-TS and YFP genes are connected by a small linker and both genes are under the control of a single E. 
tenella actin promotor (a gift from M. Kurth, TU Dresden). Sporozoites were transfected with the linearised 
construct and percentage (B) and absolute numbers (C) of YFP+ oocyst as well as numbers of shed oocysts (C) 
after in vivo passage under pyrimethamine selection are displayed. Data are shown as mean ± SEM of 1-3 mice 





3.2.5.7. Transfection with linearised plasmids for single homologous integration 
As we do not know yet if random or homologous integration of introduced DNA is favoured 
in E. falciformis, we constructed two plasmids that contain the E. falciformis 18 s rRNA 
sequence in plus- and minus-orientation upstream of the resistance cassette to facilitate single 
homologous integration (Fig. 42A). The constructs were based on pDHTSrevYFP, which 
gave the best results for transfection of E. falciformis so far (Fig. 35). E. falciformis 
sporozoites were transfected with 1012 linearised molecules of the plasmids for single 
homologous integration using the Basic Parasite Nucleofector Solution 1 and programme U-
033. Mice infected rectally with the transfected parasites were treated orally with 80 mg/kg 
pyrimethamine from d 1 to 6 p. i. The percentages of YFP-expressing oocysts after one 
selection round ranged from 0.01 to 0.11 % for the p18s+DHTSrevYFP construct (Fig. 42B) 
and 0.006 to 0.01 % for the p18s-DHTSrevYFP construct (Fig. 42C). Due to the low numbers 
of shed oocysts (p18s+DHTSrevYFP: 0.02 x 106 p18s-DHTSrevYFP:  0.03 x 106), only very 
few YFP+ oocysts were present in the samples (Fig. 42B and 42C). For a second in vivo 
passage under pyrimethamine selection, mice were infected with 1 to 3 manually selected 
YFP+ oocysts. Only 0.25 % (p18s+DHTSrevYFP) and 0.06 % (p18s-DHTSrevYFP) of all 
shed oocysts expressed the fluorescent reporter. In contrast to the observations from 
transfections with plasmids for random integration, absolute numbers of YFP+ oocysts did 







Fig. 42. Transfection with linearised plasmids for single homologous integration. (A) Plasmids for single 
homologous integration. Reporter (YFP) and resistance marker (DHFR-TS) are on the same plasmid with their 
3’ ends facing each other (pDHTSrevYFP, see Fig. 35). The sequence for the E. falciformis 18 s rRNA was 
inserted in plus- and minus-orientation upstream of the resistance cassette to facilitate single homologous 
integration. Sporozoites were transfected with the linearised constructs p18s+DHTSrevYFP (B) and p18s-
DHTSrevYFP (C). Percentage and absolute numbers of YFP+ oocysts as well as numbers of shed oocysts after 
in vivo passages under pyrimethamine selection are displayed. Shown are mean ± SEM of 1-3 mice pooled from 




3.2.6. Tracking of transgenic E. falciformis in VERO cells in vitro 
To assess the expression of the fluorescent reporter YFP during the first steps of the parasite’s 
life cycle, YFP+ E. falciformis sporozoites were purified from sporulated oocysts and VERO 
cells were infected and monitored at various time points. It is important to note that 
development was asynchronous and that time points given reflect typical stages observed at 
the respective time. Intracellular YFP+ sporozoites could be detected at 4 h p. i. (Fig. 43A). 
Most of these sporozoites displayed the typical u-shape at 20 h p. i. and subsequently 
transformed into round trophozoites with two prominent refractile bodies (26 h p. i., Fig. 
43A). Further development into immature, equally fluorescing schizonts that were 
characterised by numerous nuclei and one refractile body occurred at 40 h p. i. Mature first 
generation schizonts containing numerous, merozoites were observed already 8 hours later 
(48 h p. i. Fig. 43B). Merozoites then started to move, resulting in the loss of the exact 
arrangement, destruction of the host cell and liberation of merozoites (48 h p. i., Fig. 43C). 
All merozoites originating from one first generation schizont expressed YFP to an equal 





Fig. 43. Life cell imaging of YFP-expressing E. falciformis in VERO cells in vitro. (A) Transformation of 
intracellular sporozoites (4 h p. i.) displaying the characteristical u-shape (20 h p. i.) and subsequently 
developing into round trophozoites (26 h p. i.) (B) Immature schizonts observed at 40 h p. i. develop into mature 
schizonts at 48 h p. i. (C) Disorganised mature schizont in detaching host cell and free merozoites (all YFP-





3.2.7. Tracking of transgenic E. falciformis at the site of infection in vivo 
To assess YFP-expression of transgenic E. falciformis during asexual development in mice, 
we imaged YFP+ parasites at the site of infection ex vivo. In a test run the caecum of a naïve 
mouse was opened longitudinally and washed in PBS. A piece of intestinal tissue was placed 
on a glass slide and imaged through a glass cover slip. The caecal crypts could be easily 
identified using low magnification light microscopy and background fluorescence levels were 
very low (Fig. 44A). To image asexual YFP+ life cycle stages, mice were infected with YFP+ 
oocysts (purity < 100 %) and dissected at 120 h p. i., a time point, where third generation 
schizonts should be abundant. We could observe brightly fluorescent mature schizonts, 
containing intertwined merozoites that measured approximately 20 µm (Fig. 44B). In line 
with the observations on mature E. falciformis schizonts in VERO cells in vitro, all 
merozoites in one schizont expressed YFP with an equal intensitiy. Within merozoites, 
fluorescence was most intense in the nucleus and towards the posterior end of the merozoite 
(large refractile body). In a second experiment we could observe brightly fluorescent oocysts 
in the lumen of the crypt at 190 h p. i. (Fig. 44C). Further experiments are needed to reveal 







Fig. 44. Imaging of YFP-expressing E. falciformis schizonts and oocysts in caecum tissue ex vivo. (A) The 
caecum architecture including the crypts is clearly visible at low magnification and background fluorescence is 
minimal. Scale bar = 100 µm (B) Mature schizonts at 120 h p. i. with equal expression of YFP in all merozoites. 
Scale bar = 20 µm (C) YFP-expressing oocyst in the duct of a caecal crypt at 190 h p. i. Scale bar = 20 µm. 





3.3. In vitro culture of E. falciformis 
3.3.1. In vitro development of E. falciformis in VERO, STAT1-/-, HFF and CMT-93 cells 
In previous work in our group, several cell lines have been tested for their suitability to 
promote in vitro development of E. falciformis, including STAT1 deficient murine fibroblasts 
(STAT1 -/-) (114). Interestingly, green monkey kidney cells (VERO) have been shown to 
promote development of the rat parasite Eimeria nieschulzi until the second schizont 
generation (111). Furthermore, human foreskin fibroblasts (HFF) cells are routinely used for 
in vitro passage of T. gondii. 
To improve in vitro development of E. falciformis, VERO and HFF cells were infected with 
purified sporozoites at a MOI of 3, and invasion and development were assessed. Compared 
to an infection rate of 62 % in STAT1-/- cells, 73 % of VERO cells were infected with E. 
falciformis sporozoites, whereas only 29 % of HFF cells harboured parasites at 4 h p. i. (Fig. 
45A). At 72 h p. i. VERO cover slips harboured an average number of 106 mature schizonts, 
whereas no schizonts were observed in STAT1-/- and HFF cells (Fig. 45B). One major 
advantage of VERO cells over STAT1-/- cells was the strong adherence to the glas surface. A 
confluent monolayer was still present At 72 h p. i., whereas many STAT1-/- cells had been 
detached at this time point (Fig. 45C). Interestingly, many extracellular parasite stages were 
observed at 72 h p. i. on HFF monolayers. Thus, further experiments are required to 







Fig. 45. Invasion and development of E. falciformis in VERO, STAT1-/- and HFF cells in vitro. Cells were 
infected with E. falciformis at a MOI of 3. (A) Invasion of E. falciformis shown as percentage of infected cells at 
4 h p. i. (B) Development of E. falciformis parasites shown as total number of mature schizonts per cover slip at 
72 h p. i. (C) Representative pictures of cell monolayers at 4 h and 72 h p. i. (100x magnification). Data are 
shown as mean ± SEM of 3 samples per group representative of 1 experiment. 
 
As shown above, VERO cells allow development of E. falciformis into schizonts. However, 
this cell line is not of murine origin and thus not suitable for analysis of parasite development 
in immunological assays, such as cytokine treatment of cells (described in sections 3.1.5 and 
3.3.2). We therefore tested if CMT-93, an intestinal epithelial cell line derived from a murine 
rectum carcinoma, is a suitable model to assess invasion and development of E. falciformis (in 
cooperation with Lara Zajic). 
A multiplicity of infection (MOI) of 0.2 was used, as a higher MOI of 3 led to detachment of 
all cells within the first 24 h after infection (data not shown). Sporozoites successfully 
invaded CMT-93 cells and developed into first generation schizonts at 39 h p. i., but the 




CMT-93 cells (carcinoma) might have had a negative impact on E. falciformis development, 
we inhibited replication of cells by treatment with 2 µg/ml Mitomycin prior to seeding and 
infection with E. falciformis. This treatment improved development of sporozoites into 
mature schizonts by 227 % (Fig. 46B). Coating of culture wells with a basement membrane 





Fig. 46. Invasion and development of E. falciformis in CMT-93 cells in vitro. Prior to seeding cells were 
treated for 30 min with either media alone or 2 µg/ml mitomycin to inhibit replication. In one group (o), wells 
were coated with a thin layer of Matrigel prior to seeding of cells. Cells were infected with E. falciformis at a 
MOI of 0.2. (A) Invasion of E. falciformis in CMT-93 cells shown as intracellular parasites per high power field 
(HPF) at 4 h p. i. (400x magnification). (B) Development of E. falciformis parasites in CMT-93 cells shown as 
total number of mature schizonts per cover slip at 39 h p. i. Data are shown as mean ± SEM of 4 to 6 samples per 
group representative of 2 independent experiments. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. 
 
3.3.2. Effect of Th2-cytokines on the growth of E. falciformis in CMT-93 cells in vitro 
Infection of mice with E. falciformis provokes a strong Th1 response and as shown in 3.1.5, 
pretreatment of CMT-93 cells with the Th1 cytokine IFN-γ can inhibit development of E. 
falciformis in vitro. We hypothesised that Th2 cytokines might conversely support the 
development of E. falciformis in vitro. In a first experiment we showed that CMT-93 cells 
express the receptors for the Th2 promoting cytokines IL-13 and IL-4 and thus are able to 
respond to these stimuli (Fig. 47A). To address the effects of IL-13 and IL-4 on invasion and 
development of E. falciformis in this in vitro model, CMT-93 cells were treated with IL-13 or 
IL-4 for 8 h prior to infection with sporozoites of E. falciformis (in cooperation with Lara 




comparison to an untreated control (-10 ± 2 %). In contrast, IL-4 had no significant effect on 
the invasion of E. falciformis into CMT-93 cells (Fig. 47B). Strikingly and despite lower 
invasion rates, development of E. falciformis into mature first generation schizonts was highly 
increased (294 ± 43 %) in IL-13 treated samples. A similar effect was observed after IL-4 
treatment, with development being increased by 220 ± 26 % in comparison to an untreated 




Fig. 47. Development of E. falciformis in Th2 cytokine pre-treated CMT-93 cells in vitro. (A) Expression of 
Th2 associated cytokine receptor chains in untreated CMT-93 cells detected by RT-PCR. (B) Invasion of E. 
falciformis in CMT-93 cells that were pre-treated for 8 h with either media alone or supplemented with 50 ng/ml 
IL-4 or IL-13 prior to infection. (C) Development (schizogony) of E. falciformis assessed at 39 h post infection 
of CMT-93 cells that were pre-treated for 8 h with either media alone or supplemented with 50 ng/ml IL-4 or IL-
13 prior to infection. The figure represents pooled data from 2 independent experiments that are shown as mean 





3.4. Infection of EGFP mice with E. falciformis 
C57BL/6 EGFP mice express the fluorescent reporter “enhanced green fluorescent protein” 
(EGFP) ubiquitously (119). Thus, immune cells from EGFP mice that have been infected with 
E. falciformis could be used in adoptive transfer experiments to investigate the interaction 
between host immune system and parasite using microscopy. However, there are no data on 
the infection of EGFP mice with E. falciformis available. To test the suitability of this mouse 
strain, mice were infected with E. falciformis oocysts and infectivity and development of 
immune protection against subsequent challenge infections were analysed. After infection 
with 50 E. falciformis oocysts, EGFP mice shed 0.89 ± 0.06 x 107 oocysts (Fig. 48A). This is 
a 3-fold increase in comparison to an internal C57BL/6 wild type control group (0.30 ± 0.04 x 
107 oocysts). However, despite increased susceptibility of EGFP mice to primary infection, 
the development of immunity induced by two subsequent challenge infections was 
comparable to wt mice. The number of shed oocysts was reduced by 96 % in EGFP mice and 
by 98 % in wild type mice that had received a challenge infection four weeks after primary 
infection. Immune protection was stable as demonstrated by a third infection, with oocyst 
numbers being reduced by 99.8 % in EGFP mice and 98.6 % in wild type mice compared to 
the primary infection (Fig. 48A). 
Next, MLNC from EGFP mice that were infected with E. falciformis, were tested for their 
capacity to transfer protective immunity in adoptive transfer experiments. In comparison to a 
PBS control group, transfer of 5 x 107 MLNC from infected EGFP mice led to a 40 % 
reduction in the number of shed oocysts after challenge infection of recipient wild type mice 
(Fig. 48B). Transfer of naïve MLNC from EGFP mice did not have a protective effect. 
Interestingly, decreased oocyst shedding correlated with a significantly increased body weight 
loss on the peak days of the infection in comparison to the control groups (Fig. 48B). To 
validate successful homing of immune cells from EGFP mice in adoptive transfer 
experiments, 1.5 x 107 MLNC isolated from E. falciformis-infected EGFP mice on d 8 p. i. 
were transferred to naïve wt mice. FACS analysis of MLN and spleen cells from recipient 
mice isolated 2 days after transfer revealed a frequency of YFP+ cells of 1.36 % (MLN) and 
1.34 % (spleen). Thus, 0.4 % (MLN) and 11.6 % (spleen) of all transferred cells could be 






Fig. 48. E. falciformis infections in C57BL/6 EGFP mice. (A) Number of shed oocysts on d 8 to 10 p. i. after 
(A) primary (1st) and challenge (2nd, 3rd) infections with 50 E. falciformis oocysts of C57BL/6 EGFP and wild 
type mice. (B) Adoptive transfer. Depicted are the number of shed oocysts (d 8 to 10 p. i.) and body weight loss 
after challenge infection of C57BL/6 wild type mice with 50 E. falciformis oocysts. Challenged mice received 
MLN cells from naïve and E. falciformis infected (primed) EGFP mice 1 day prior to challenge infection. (C) 
Frequency of transferred YFP+ cells in MLN and spleen of recipient mice that received MLN cells from EGFP 
or wild type mice. Graph shows the percentage of YFP+ cells detected in relation to all transferred cells. Data 






4.1.  The role of IFN-γ  signalling in infections of mice with E. falciformis 
4.1.1. The absence of IFN-γ  or IFN-γR during E. falciformis infection is associated with 
the development of a dominant Th17 response  
Our group and others have previously reported that infection of wt mice with various Eimeria 
species led to the development of an IFN-γ-dominated, protective immune response that was 
predominantly derived from CD8+ T cells in E. falciformis infection (12, 96). In line with 
these studies we show that E. falciformis-infected wt mice developed a transient weight loss 
correlating with the peak days of oocyst shedding, but recovered by day 12 p. i. and critically 
developed protective immunity to subsequent re-infections. In contrast, mice deficient in 
either IFN-γ or IFN-γR developed a severe weight loss and pathology during E. falciformis 
infection associated with high levels of Th17-associated cytokines, neutrophilic infiltrate, loss 
of crypt architecture and luminal bleeding. These findings are in line with previous reports of 
infections with the large intestine-dwelling protozoan parasite Eimeria pragensis, in which 
IFN-γ depleted mice developed severe body weight loss (88). 
We show, that the development of pathology during infection with E. falciformis in the 
absence of IFN-γ or IFN-γR is associated with a switch towards a dominant Th17 response, 
characterised by high levels of secreted IL-17A and IL-22 protein following restimulation of 
lymphocyte cultures with parasite antigen. Critically, antibody-mediated concurrent 
neutralisation of IL-17A and IL-22 resulted in a significant reduction in E. falciformis-
induced inflammation on the peak days of infection and a partial amelioration of body weight 
loss and morbidity. Increased pathology induced by E. falciformis infection was associated 
with a dramatic increase in Gr-1+ lamina propria neutrophils mediated by IL-17A and IL-22 
which have both previously been shown to drive neutrophil influx in mucosal tissues (120). 
CD4+ RORγt+ Th17 cells were found to be the predominant cellular source of IL-17A and IL-
22 following E. falciformis-induced intestinal inflammation, although it is possible that other 
innate cell types such as NKp46+-expressing NK cells or recently identified subsets of 
Lymphoid Tissue Inducer cells could also provide additional early sources of these cytokines 
and thus contribute to the development of inflammation (33, 121). Surprisingly, IFN-γR-/- 
mice had increased numbers of CD4+ IFN-γ+ cells, suggesting a missing negative feedback 




additionally found to co-express both RORγt and T-bet. The presence of such a Th1/Th17 
subset during E. falciformis infection suggests a degree of T cell plasticity and interestingly, 
cells expressing both IL-17A and IFN-γ have recently been ascribed important roles in driving 
intestinal inflammation (122). 
 
4.1.2. IL-17A and IL-22 drive intestinal pathology in E. falciformis-infected IFN-γR-/- 
mice  
Th17 responses have been implicated in many diseases of intestinal inflammation. For 
example, polymorphisms in IL-23R are highly associated with altered susceptibility to colitis 
(123, 124). During E. falciformis infection of IFN-γR-/- mice we observed an increased 
expression of IL-23R in the large intestine. As IFN-γ can directly prevent Th17 expansion via 
the suppression of IL-23R (26) it is possible that IFN-γ may regulate parasite-induced Th17 
responses in this manner during E. falciformis infection. IL-17A production is highly 
correlated with disease severity in patients suffering from both ulcerative colitis and Crohn’s 
disease, and RORγt-expressing Th17 cells were shown to be essential for the development of 
colitis in murine models (39). In contrast, IL-22 has seemingly pleiotropic functions during 
colitis. It is abundantly expressed in the mucosa of patients suffering from Inflammatory 
Bowel Disease and drives production of pro-inflammatory cytokines and matrix 
metalloproteinases (125). 
MMPs are potent mediators of intestinal pathology and mice deficient for MMP-9 develop 
less severe inflammation and disease during a mouse model of colitis (63). In line with these 
findings a strong increase in MMP-9 was observed in IFN-γR-/- mice following E. falciformis 
infection. IL-22 but not IL-17A was shown to be necessary to drive small intestinal 
inflammation and tissue damage following oral infection of mice with Toxoplasma gondii via 
induction of pro-inflammatory cytokines and MMP-2 (41, 126). In contrast, there was no 
difference in the expression levels of MMP-2 between wt and IFN-γR-/- mice in our model. 
Thus MMP-9 rather than MMP-2 might play a role in the induction of intestinal 
immunopathology in infections of IFN-γR-/- mice with E. falciformis. 
Conversely, IL-22 also has protective roles in murine ulcerative colitis models via enhanced 
production of mucus and induction of mucosal wound healing responses (49, 50). Our data 
suggest that IL-17A and IL-22 have redundant roles during E. falciformis driven 
inflammation as dramatic reductions in cellular infiltrate and, in particular, attenuation of 




worth noting however, that we cannot rule out the possibility that other Th17 cytokines such 
as IL-17F and GM-CSF, which also have important roles in inflammation, contribute to E. 
falciformis-induced inflammation (39, 127). The severe Th17 driven inflammation and 
pathology seen during the self-limiting E. falciformis infection in the absence of IFN-γ has 
many parallels to murine models of colitis, and thus may prove to be a powerful model for 
dissecting the immunological mechanisms behind Th1/Th17 disease. 
 
4.1.3. IL-22 mediates anti-parasite effects in E. falciformis-infected IFN-γR-/- mice 
Surprisingly, the loss of IFN-γ or IFN-γR and subsequent increase in Th17-driven pathology 
and mortality following E. falciformis infection did not result in attenuated host defence, but 
rather a decreased parasite shedding. Similarly, previous reports utilising the large intestine 
dwelling species E. pragensis noted that host defence was not impaired in the absence of IFN-
γ, although clinical signs were exacerbated (128). Although CD8+ cell-derived IFN-γ may 
partially protect against E. falciformis (12), we report herein that IFN-γ is dispensable and that 
the switch to Th17-dominated responses in the absence of IFN-γ results in an enhanced 
control of asexual replication, decreased oocyst shedding and comparable protection from re-
infection, at the expense of increased pathology.  
Although the mechanism by which IL-17A and IL-22 can inhibit E. falciformis development 
in vitro and in vivo is currently unclear it has previously been reported that both cytokines 
have critical roles in host protection to other pathogens. IL-17A and IL-22, but not IFN-γ, are 
essential for host defence during oral candidiasis (36, 129). Similarly, IL-22 also has many 
emerging and crucial functions during host defence against microbial pathogens. The cytokine 
is essential for maintaining mucosal barrier function and for the enhanced epithelial cell 
proliferation and cytokine production required to control Klebsiella pneumoniae infection 
(32). A potential role in host defence for both IL-17A and IL-22 during protozoan parasite 
infection has been indicated by the strong correlation between levels of these cytokines and 
protective immunity in human populations infected with Leishmania donovani (130). IL-17A-
/- mice fail to control Trypanosoma cruzi infection, which leads to multiple organ failure and 
mortality (131). However, to date no protective role for IL-22 has been shown in parasite 
infections. 
To further explore the anti-parasite role of IL-17A and IL-22 we developed an in vitro culture 
system in which E. falciformis is able to invade and develop in the immunocompetent 




biologically relevant concentrations of a panel of cytokines had no significant effect on the 
invasion rate of E. falciformis, pre-treatment with IFN-γ, IL-17A and IL-22, but not IL-10, 
resulted in a significant reduction in E. falciformis schizont development. Interestingly, 
treatment with IL-6 inhibited development of E. falciformis to the same degree as treatment 
with IL-17 or IL-22 (unpublished data, in cooperation with Florian Uhlitz). Although IL-17A 
and IL-22 both had anti-parasite functions in vitro, antibody neutralisation studies suggested 
that IL-22 had the dominant anti-parasite effect in vivo. This is of particular relevance as IL-
22R expression is restricted to non-haematopoetic cells including intestinal epithelial cells 
(45), which are the host cells for E. falciformis infection. Thus, IL-22 may have potent anti-
parasite effects by directly targeting infected epithelial cells in the caecum. 
IL-22 is a potent inducer of the Reg family of antimicrobial peptides and early production of 
IL-22 from innate cell sources, such as a recently identified CD4+ LTi population, has been 
shown to inhibit attachment of the gram-negative bacterium Citrobacter rodentium and to 
prevent epithelial cell damage in the gastrointestinal tract via induction of RegIIIβ and 
RegIIIγ (33, 34). To our knowledge there is only a single report on direct antimicrobial effects 
of RegIII proteins, demonstrating lysis of gram-positive bacteria after binding of RegIIIγ to 
peptidoglycan in the cell walls of the microbes (47). A related group of peptidoglycan-binding 
proteins, the peptidoglycan recognition proteins (PGRPs) were shown to be effective against 
gram-positive and gram-negative bacteria by activating protein-sensing two component 
systems and thus causing bacterial death (132). PGRPs bound to the outer, peptidoglycan-free 
cell wall of gram-negative bacteria, which suggests binding of these antimicrobial proteins to 
additional, yet unknown receptors / molecules. In our model, the drastic increase in the 
expression of RegIIIβ and RegIIIγ in IFN-γR-/- mice infected with E. falciformis was partially 
reversed after neutralisation of IL-22, which correlated with increased parasite shedding. 
Further research is required to determine whether RegIII family proteins also have anti-
parasite properties and contribute to host defence during E. falciformis infection. 
Another important family of AMPs that can be induced by IL-17 and IL-22 are defensins 
(43). In our in vitro model, expression of murine β-defensin 3 (Defb3) was increased in IL-
17A treated CMT-93 cells which correlated with decreased parasite development in these 
cells. Interestingly, pretreatment of T. gondii tachyzoites with synthetic human β-defensin 2, 
the human homologue of murine Defb3, decreased parasite viability and infectivity in a 
human intestinal cell line (133). Pretreatment of E. falciformis sporozoites or parasite-infected 
CMT-93 cells with recombinant Defb3 could reveal, whether this AMP possesses anti-




homogenised intestinal tissue in vivo, purification of intestinal epithelial cells might be 
required in future experiments. A recent study reported increased expression of Defb3 in 
isolated colonic epithelial cells from two mouse models of colitis and in line with our 
observations, IL-17A was shown to induce Defb3 in CMT-93 cells (134). The slight increase 
in the expression of Defb4 in IL-17A treated, uninfected cells was reversed after infection 
with E. falciformis. Intriguingly, data on T. gondii strongly suggest that tachyzoites of the 
type I strain evade the immune system by suppressing the expression of human β-defensin 2 
(133). However, despite decreased Defb4 expression, development of E. falciformis was 
inhibited in IL-17A-treated cells in vitro suggesting that Defb4 does not have a dominant anti-
parasitic effect in this cell line. In vivo, Defb4 expression was slightly increased in IFN-γR-/- 
mice infected with E. falciformis compared to wt mice. Further experiments are needed to 
clarify the role of Defb4 in our model. 
 
4.1.4. Possible mechanisms by which IFN-γ  might suppress pathological Th17 
responses 
Herein we show a key role for Th17 responses in driving pathology and limiting parasite 
replication in IFN-γR-/- mice infected with E. falciformis. However, the precise mechanism by 
which loss of IFN-γ signalling leads to the induction of a compensatory, albeit pathological 
Th17 response during E. falciformis infection remains to be demonstrated. The transcription 
factor T-bet is essential for Th1 differentiation and thus for efficient IFN-γ production. 
Importantly, T-bet not only drives the differentiation of Th1 cells but at the same time 
represses development of Th17 cells by interaction with Runx-1, which prevents the 
activation of Rorc (135). Furthermore, T-bet limited the survival of pathogenic Th17 cells 
through inhibition of Il23r transcription in a model of autoimmune disease (136). 
In our model, expression of IL-23R was increased in E. falciformis-infected IFN-γR-/- mice 
compared to wt mice. In schistosomiasis, T-bet-/- mice displayed exacerbated egg-induced 
hepatic immunopathology that correlated with enhanced Th17 responses, neutrophilic influx 
and reduced Foxp3 expression, suggesting an important role for T-bet in the regulation of 
immune homeostasis (137). Likewise, Th17 cells were reciprocally suppressed by the 
expansion of other T cell lineages including Foxp3+ Treg cells (138, 139). Thus, IFN-γ can 
effectively suppress Th17 responses through the induction of regulatory T cells. In line with 




IFN-γR. IFN-γ may drive Treg via a preferential expansion of Foxp3+ cells due to induction of 
apoptosis in Foxp3- responders in a STAT1 and nitric oxide (NO) dependent manner (140). 
NO might also contribute to the regulation of immune homeostasis in infections with E. 
falciformis, as the severe Th17-mediated pathology observed in E. falciformis-infected IFN-
γR-/- mice correlated with drastically reduced expression of iNOS at the site of infection. In 
line with this, E. falciformis-infected iNOS-/- mice displayed exacerbated pathology 
correlating with increased numbers of IL-17A and IL-22-producing CD4+ T cells. As NO is 







Based on our results, we developed the model shown in figure 49. Infection of C57BL/6 wild 
type mice with E. falciformis leads to a dominant CD8+ T cell-derived, IFN-γ-driven response 
that is sufficient to mediate host protection and correlates with IFN-γ-driven infiltration of 
Ly6C+ (Gr-1-) monocytes into the lamina propria (Fig 49, left panel). In the absence of IFN-
γR the number of IL-17A- and IL-22-producing Th17 cells (and IFN-γ-producing Th1 cells) 
is dramatically increased in the draining lymph nodes and the lamina propria (Fig 49, right 
panel). E. falciformis antigen-specific IL-17A and IL-22 drives infiltration of Gr-1+ 
neutrophils into the intestinal tissue, thus increasing pathology. Th17 responses are associated 
with a reduced parasite load, suggesting that Th17 responses enhance host defence to E. 
falciformis. E. falciformis-elicited IL-22 induces the expression of anti-microbial peptides of 




Fig. 49. Model of the immune response in Eimeria falciformis infections of wild type and IFN-γR-/- mice. 






4.2. Establishment of a transfection system for E. falciformis 
 
4.2.1. Killing of wild type E. falciformis using pyrimethamine 
Pyrimethamine has been used for in vivo selection of several apicomplexan parasites 
including E. tenella and P. berghei that have been transfected with plasmids carrying a 
fluorescent reporter and/or the resistance marker DHFR-TS. Application of 70 µg/ml 
pyrimethamine in the drinking water was sufficient to select transgenic P. berghei parasites 
(102). In contrast, treatment of mice that had been infected with wild type E. falciformis with 
up to 2 mg/kg in drinking water did not reduce oocyst shedding. To facilitate better control of 
the pyrimethamine dosage, we applied the drug using oral gavage. As pyrimethamine is 
poorly water soluble, we prepared a suspension of the drug in water (142). In an early study, 
treatment of mice with 25 mg/kg pyrimethamine suspended in water decreased the number of 
shed oocysts by 53 % (143). We had to increase the dose to 80 mg/kg to achieve > 95 % 
killing of wild type E. falciformis. Being aware that the potential error in the effective dose 
applied is high when using an aqueous suspension, we dissolved pyrimethamine in a 2:1 
mixture of DMSO and PEG400, a method that has been successfully established in the 
treatment of gerbils (Sandra Schorderet, Novartis Animal Health, personal communication). 
This method led to killing of 99 % of wild type E. falciformis. 
Taking into account the intestine as the site of replication of Eimeria, intraperitoneal 
application of the drug might increase availability and effectiveness. In line with this 
hypothesis, replication of the small intestinal parasite Eimeria vermiformis could be 
completely inhibited by a low i. p. dose of pyrimethamine (5 mg/kg, Fiona Tomley, Institute 
of Animal Health Compton UK, personal communication). In our system, neither i. p. 
application of 5 mg/kg pyrimethamine dissolved in EtOH, nor i. p. injection of up to 30 
mg/kg pyrimethamine dissolved in DMSO/PEG400 could achieve complete killing of wild 
type E. falciformis. 
Dietary application of pyrimethamine has been reported for the avian species E. tenella  (82, 
108). Notably, killing of wild type E. tenella was not complete, as 3 of 5 infected birds still 
shed detectable numbers of oocysts when a dose of 100 ppm was used (82). Thus, in 
subsequent experiments, E. tenella that had been transfected with the resistance marker 
DHFR-TS were selected using 150 ppm dietary pyrimethamine. However, the study did not 
provide data on the effectivity of the 150 ppm dosage against wild type E. tenella. In contrast, 




63%). A higher dose of 400 ppm led to a maximal reduction in oocyst shedding of 87%. 
Increased dietary concentration of pyrimethamine correlated with decreased food 
consumption, thereby limiting the effective pyrimethamine dose to 54 mg/kg/d (calculated 
from concentration of the drug and amount of food taken up). 
As pyrimethamine is hydrophobic, bioavailability in the intestine might be poor, thus 
decreasing drug effectiveness. To address potential problems in the bioavailability of drug, we 
generated inclusion complexes (PHIC) of pyrimethamine in the widely used hydrophilic drug 
carrier 2-hydroxypropyl-β-cyclodextrin that has also been shown to improve solubility of the 
antimalarial drug halofantrine (144). Despite being effective against T. gondii in vitro, PHIC 
did not reduce the development of wild type E. falciformis in mice. This was likely due to the 
low maximal pyrimethamine dose of 250 µg per day, which corresponds to 8 mg/kg for a 30 g 
NMRI mouse. Higher doses would require production of PHIC at a larger scale, or with more 
sophisticated methods, such as freeze-drying (144). 
 
4.2.2. Rectal infection of mice with E. falciformis sporozoites 
Sporozoites are sensitive to the acidic environment of the stomach and thus would be killed, 
when applied via oral gavage. Two possibilities to circumvent this problem have been 
described. Cloacal administration of sporozoites of the avian large intestinal species E. tenella 
led to successful establishment of an infection. In contrast, sporozoites of the small intestinal 
species E. maxima administered cloacally did not complete development (82). In the latter 
case, neutralisation of the stomach using sodium bicarbonate prior to infection of chickens by 
oral gavage enabled the development of E. maxima into oocysts. This method has also been 
successfully applied in infections of rats with purified sporozoites of E. nieschulzi that infects 
epithelial cells of the small intestine (Michael Kurth, TU Dresden, personal communication). 
As E. falciformis is located in the caecum and upper colon, we established rectal infection of 
mice. Sporozoites successfully completed their life cycle, but the yield in oocysts was 
decreased, when compared to the oral infection route. This is in line with results obtained 
from cloacal infections of chickens with E. tenella (82). 
 
4.2.3. Transfection of unsporulated oocysts 
As expected, transfection of unsporulared oocysts using electroporation did not result in 
transgenic parasites, most likely due to the extremely resistant structure of the oocyst shell 




oocyst that can be weakened using pepsin, allowing infiltration of a fluorescent reporter at 
this site. Thus, digestion of the oocyst wall of sporulated oocysts with pepsin prior to 
transfection might facilitate introduction of the plasmid DNA into sporozoites (77). It is 
important to note, that the sporocyst wall, which protects sporozoites inside the oocyst, might 
form an additional barrier to transfection. Interestingly, preliminary results from our group on 
transfection of purified E. falciformis sporocysts suggest that the plasmid DNA can traverse 
this second cyst wall of (Peng Fei Kong, unpublished data). 
 
4.2.4. Transfection of sporozoites 
The original plasmids (pmic1YFPmact & pactDHTSact) used for transfection of E. 
falciformis had been successfully used to generate stable transgenic lines of E. tenella (82). 
Using the Amaxa Nucleofector II system (programm U-033) for co-transfections of these two 
linearised plasmids into E. falciformis, we could achieve percentages of fluorescent oocysts 
up to 0.002 after the first passage under pyrimethamine selection. This is in contrast to data 
from co-transfection of E. tenella, where up to 9 % of all shed oocysts expressed YFP (82). 
The same plasmids were used for co-transfection of the rat parasite Eimeria nieschulzi, which 
resulted in 0.05 % YFP+ oocysts after one passage under pyrimethamine selection (111). 
Similarly, a study co-transfecting E. tenella with the reporter plasmid containing YFP under 
control of the histone 4 promoter and a second plasmid containing the resistance marker 
DHTS, reported 0.04 % YFP+ oocysts after the first passage under pyrimethamine selection 
(108). 
We constructed plasmids containing both, the reporter (YFP) and the resistance marker 
(DHTS) in different orientations. Transfection of E. falciformis with these linearised plasmids 
and passage of the transfected sporozoites in mice under pyrimethamine selection led to ≤ 
0.025 % YFP+ oocysts in the first progeny, when pDHTSrevYFP was used. Increasing the 
plasmid copy number used in transfections did not lead to higher transfection efficiencies. 
This is one magnitude lower as compared to a similar approach using E. tenella. Transfection 
with a single plasmids containing both, reporter and resistance marker, led to 0.1-0.4 % YFP+ 
oocysts after one passage under pyrimethamine selection. Even without selection during the 
first passage, 0.001-0.1 % of all oocysts expressed YFP after the first passage (82). 
Transfection of E. tenella with reporter plasmids only led to 0.004 % YFP+ oocysts after the 
first passage in one study and to 0.01-0.2 % YFP+ parasites in the first progeny in a second 




Using southern blot analysis and quantitative real time PCR, it was demonstrated that the 
introduced DNA was randomly integrated in the E. tenella genome at an average number of 4 
plasmid copies per parasite genome (82). In our model, we could not perform southern blot 
analysis to check for integration of the constructs due to insufficient numbers of YFP+ 
oocysts derived from the passage in mice. 
Taken togethter, random integration of transfected DNA seems to be favoured in E. tenella. 
This is in line with results on transfection of the related apicomplexan parasite T. gondii, 
where crossover events are rare and thus introduced DNA tends to integrate randomly. 
Recently, a T. gondii strain that shows considerably improved frequencies of homologous 
recombination has been generated (146). This strain is deficient in the Ku80 gene, which 
encodes for subunit of the Ku70/Ku80 heterodimer that binds to broken and free DNA ends, 
mediating their repair. As the genome of E. falciformis is being sequenced by our group at the 
moment, it will soon be clear if E. falciformis possesses the Ku80 gene and thus a similar 
approach could be taken. Furthermore, the availability of sequence information from E. 
falciformis would open up the possibility to construct plasmids for double homologous 
recombination that containing flanking sequences from E. falciformis and thus may facilitate 
more effective integration of the introduced DNA. 
Our model may reflect the situation for transfection of Plasmodium falciparum 3D7, where 
integration events are rare. The introduced plasmids are maintained as concatamerised 
episomes and only integrate after several weeks of in vitro culture under pyrimethamine 
selection (147). Thus, circular DNA is routinely used for transfection. Interestingly, 
transfection of E. falciformis with circular pDHTSrevYFP resulted in up to 0.13 % YFP+ 
oocysts after the first passage under pyrimethamine selection. Further selection of these YFP+ 
oocysts in several passages under pyrimethamine selection in vivo did increase the percentage 
of YFP+ oocysts up to 13.2 %. However, the percentages decreased again during subsequent 
passages. These results indicate that either integration events are rare in E. falciformis and 
introduced DNA might be maintained as episomes, or that the plasmids had been integrated 
into the genome, but get deleted during replication of the parasite. E. falciformis undergoes 
asexual and sexual replication during its life cycle in the mouse. Recombination events that 
might lead to the deletion of the potentially integrated DNA are likely to take place during 
meiosis (148). We were able to track YFP+ schizonts (asexual stages) in intestinal ex vivo 
samples from mice that had been infected with high numbers of YFP+ oocysts and in VERO 
cells that had been infected with purified YFP+ sporozoites. Interestingly, all merozoites 




maintained as episomes or integrated seems to be stable during asexual development, but 
might get lost during sexual replication. These observations are in contrast to E. tenella, 
where repeated passage of YFP+ oocysts under pyrimethamine and/or FACS selection led to 
stable transgenic lines within few passages (82, 108). Furthermore, transgenic E. tenella were 
shown to express YFP throughout their life cycle in vitro (149). Further experiments are 
needed to reveal, if the introduced DNA is integrated into the genome or maintained as 
episomes, which would provide important information for the development of a successful 
transfection strategy for E. falciformis. 
4.2.5. Potential application of fluorescent reporter-expressing E. falciformis 
As first experiments have indicated in this work, E. falciformis that express fluorescent 
reporters would enable tracking of the parasites at the site of infection or in cell culture in 
vitro. This tool could be used to clarify details of the life cycle of E. falciformis in ex vivo 
specimens, or for the analysis of host-pathogen interactions using intravital microscopy. 
Tracking of fluorescent parasites at the site of infection has been reported for various parasites 
including Plasmodium spp., Leishmania major and T. gondii (150). However, reports on 
intravital microscopy at intestinal barrier surfaces are rare, which is likely to be due to the 
high autofluorescence and the thickness of the gut wall, making optical access quite 
challenging. Hopefully, technical advances in imaging equipment and techniques will resolve 
this problem in near future. Figure 50 schematically outlines a potential analysis of 
interactions between fluorescent E. falciformis sporozoites and fluorescent immune effector 








Fig. 50. Possible application using fluorescent parasites and EGFP mice. 1) Infection of wild type recipient 
mice with transgenic oocysts expressing fluorescent reporter. 2) Generation and adoptive transfer of protective 
immune cells from E. falciformis-infected EGFP-expressing mice. 3) Microscopic analysis of interactions 





4.3. In vitro culture of E. falciformis 
E. falciformis sporozoites invaded all cell lines tested, but considerable development into 
mature first generation schizonts occurred only in VERO and CMT-93 cells. The numerous 
extracellular parasite stages observed at 72 h p. i. in HFF cells suggest a possible egress of 
merozoites from mature schizonts earlier than 72 h p. i.  Thus, further experiments using 
various time points will reveal, if development of E. falciformis is possible in this cell line. 
Furthermore, monitoring in vitro cultures at later time points will demonstrate if E. falciformis 
develops further than into the first mature asexual generation. Reports on the in vitro culture 
of the murine parasite E. vermiformis in various cell lines and primary cells described 
termination of development at the first schizont stage (98, 113). This is in contrast to the avian 
species E. tenella, which could complete its life cycle in PCKC, albeit with very low 
efficiency (112). 
We did not detect any schizonts in STAT1-/- cells, which is in contrast to previous work with 
E. falciformis (114). One possible explanation for these observations is the frequent 
detachment of STAT1-/- cells during the first 48 h after infection with E. falciformis at MOI of 
3.  This MOI was initially used in infections of VERO, STAT1-/- and HFF cells. Interestingly, 
the fact that higher invasion rates do not necessarily correlate with better development was 
demonstrated for in vitro culture of E. tenella (112). To take this observation into account and 
to prevent the detachment of host cells, the MOI was decreased to 0.2 for infections of the 
murine intestinal epithelial cell line CMT-93. In this study, this cell line was used for the first 
time for in vitro culture of E. falciformis. It has major advantages over STAT1-/- and VERO 
cell lines. CMT-93 cells are of murine origin and thus suitable for immunological experiments 
in infections with E. falciformis. 
In our model, treatment of CMT-93 cells with the Th2 cytokines IL-4 or IL-13 prior to 
infection did strongly increase development of E. falciformis into mature first generation 
schizonts, thus demonstrating a possible way of manipulation of host cells. Furthermore, 
CMT-93 cell monolayers adhered very strongly to uncoated culture dishes, thus making work 
easier. However, the rate of development of invaded sporozoites was very low. One reason 
for this might be the two-dimensional nature of normal cell cultures. CMT-93 cells have a 
different shape and express junctional molecules, when cultured polarized in transwell dishes 
(Mike Lehmann, HU Berlin, personal communication). The type of culture may as well 




The improved development of E. falciformis in CMT-93 cells that had been treated with 
Mitomycin C demonstrates that the rate of replication and/or the cell cycle stage might also 
influence parasite development. Furthermore Eimeria parasites have a very complex life cycle 
with several asexual generations and a subsequent gamogony. Merozoites of each asexual 
generation egress from cells and invade new cells for the next round of replication. It is not 
known, if the different generations have different requirements regarding their host cell. This 
could be an important limiting factor in vitro. Sporozoites of E. falciformis for example are 
thought to invade cells of the caecal crypts, but it is not known if stem cells or terminally 
differentiated cells get invaded (151). Nothing is known about the exact location of 
subsequent life cycle stages. Thus, it is possible that the different life cycle stages of murine 
Eimeria spp. have different host cells with distinct characteristics. These circumstances would 
be very hard to mimic using normal cell lines and could be overcome by the ex vivo use of 
intestinal samples or the growth of intestinal tissue in vitro. 
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Female specific pathogen free C57BL/6 wild type mice (purchased from Charles River), 
C57BL/6 IFN-γ-/- mice (T. Schüler, Charité University Medicine, Berlin), C57BL/6 IFN-γR-/- 
mice and iNOS-/- mice  (U. Klemm, Max Planck Institute for Infection Biology, Berlin), as 
well as C57BL/6 EGFP mice (119) bred at the Department of Molecular Parasitology were 
used for parasite infections. E. falciformis was maintained by serial passage in NMRI mice 
(bred at the Department of Molecular Parasitology) using an infection dose of 300 oocysts. 
All experiments were performed in accordance with the national animal protection guidelines, 
approved by the animal ethics committee.  
 
5.1.2. Parasites 
E. falciformis, originally obtained from Bayer Animal Health (Dr. Gisela Greif) was 
maintained at the Department of Molecular Parasitology by serial passage in mice. 
T. gondii tachyzoites (RH strain) were maintained at the Department of Molecular 




Antarctic phosphatase NEB 
Brefeldin A and Ionomycin Sigma-Aldrich 
Cell culture media and supplements PAA Laboratories 
Cellulose (DE52) Whatman 
Collagenase VIII Sigma-Aldrich 
Dream Taq Polymerase Fermentas 
Formaldehyde Sigma-Aldrich 
Glas beads ø 0.5 mm Braun Sartorius 
Glycotaurocholate a gift from M. Kurth, TU Dresden 
3H-Thymidin ICN Biochemicals 




Neopredisan Menno Chemie 
Nylon wool Robbins 
Pepsin Sigma-Aldrich 
Percoll GE Healthcare 
Potassiumdichromate Merck 
Proteinase K Sigma-Aldrich 
Pyrimethamine AK Scientific 
Recombinant mouse IFN-γ Peprotech 
Recombinant mouse IL-4 Peprotech 
Recombinant mouse IL-6 Peprotech 
Recombinant mouse IL-13 Peprotech 
Recombinant mouse IL-17A Peprotech 
Recombinant mouse IL-22 Peprotech 
Restriction enzymes NEB 
Klenow enzyme NEB 
Schiffs Reagent Merck 




5.1.4. Commercial kits 
Kit Company 
Basic Parasite Nucleofector Kit 1 & 2 Amaxa 
BCA Protein Assay Thermo Scientific 
Cytofix/Cytoperm Kit BD Bioscience 
innuPrep DNA / RNA Kits JenaAnalytik 
FastStart SYBR Green Master Mix Roche 
FoxP3 fix/perm Kit eBioscience 
RNA-to-cDNA Kit Applied Biosystems 
Maus IFN-γ ELISA eBioscience 
Maus IL17A DuoSet ELISA R&D 
Maus IL-22 DuoSet ELISA R&D 
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Nucleobond EF Midi Prep Machery & Nagel 
p-Drive cloning kit Quiagen 
 
5.1.5. Antibodies 
Antigen-conjugate (clone) Source 
IL-22 (AM22.1) Jean-Christophe Renauld, Brussels 
IL17A (MM17AF3) Catherine Uyttenhove, Brussels 
IgG (mouse) Dianova 
CD3 BD Biosciences 
CD8-PE DRFZ, Berlin 
GR-1-Cy5 DRFZ, Berlin 
CD4-FITC BD Biosciences 
IL-17A-PE BD Biosciences 
CD25-APC BD Biosciences 











5.1.6. Primers for quantitative RT-PCR  
Gene Forward Reverse 
Actb TCTTGGGTATGGAATCCTGTGGCA TCTCCTTCTGCATCCTGTCAGCAA 
Cxcl9 TCCTTTTGGGCATCATCTTCC TTTGTAGTGGATCGTGCCTCG 
Cxcl10 CCAAGTGCTGCCGTCATTTTC GGCTCGCAGGGATGATTTCAA 
Defb3 GTCTCCACCTGCAGCTTTTAG AGGAAAGGAACTCCACAACTGC 
Defb4 GCAGCCTTTACCCAAATTATC ACAATTGCCAATCTGTCGAA 
Reg3b CTCTCCTGCCTGATGCTCTT GTAGGAGCCATAAGCCTGGG 
MATERIAL & METHODS 
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Reg3g TCAGGTGCAAGGTGAAGTTG GGCCACTGTTACCACTGCTT 
Hprt TGGACAGGACTGAAAGACTTGCTC AGTCTGGCCTGTATCCAACACTTC 
Ifngr1 CTGGCAGGATGATTCTGCTGG TGCAGGAATCAGTCCAGGAAC 
Il4ra1 TGGATCTGGGAGCATCAAGGT TAGGGGCTTCACATTACCACTG 
Il6 TAGTCCTTCCTACCCCAATTTCC TTGGTCCTTAGCCACTCCTTC 
Il10rb ACCTGCTTTCCCCAAAACGAA TGCATCTCAGGAGGTCCAATG 
Il13ra AGTGATTGGAGTGAAGCACAG TTCACAGGGTCACATTGAAGG 
Il17ra AGTGTTTCCTCTACCCAGCAC GTGGTTTGGGTCCCCATCA 
Il22r1 ATGAAGACACTACTGACCATCCT CAGCGAGCTGAAACGATCA 
Il23a ATGCTGGATTGCAGAGCAGTA ACGGGGCACATTATTTTTAGTCT 
Il23r TTCAGATGGGCATGAATGTTTCT CCAAATCCGAGCTGTTGTTCTAT 
Mmp2 GCAGTGCAATACCTGAACACTTTCTA TGCGGGGGAAGAAGTTGTAGT 
Mmp9 GCTTCAGAAGCAGCTCTCC GTTTTGGATCCAGTATGTG 
Nos2 CCCTTCCGAAGTTTCTGGCAGCAGC GGCTGTCAGAGCCTCGTGGCTTTGG 




pmic1YFPmYFPact Fiona Tomley, IAH Compton, UK 
pactDHTSact Fiona Tomley, IAH Compton, UK 




ABI 7300 Applied Biosystems 
Axio Imager Z2 + ApoTome Carl Zeiss 
Axio Imager Z1 Carl Zeiss 
BD FACS Aria II BD Biosciences 
BD Fortessa SRP BD Biosciences 
Casy Model TT Innovatis 
Autostainer Plus DAKO 
Gel documentation Herolab 
DMIL IMC Leica 
Mastercycler Eppendorf 
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MicroBeta TriLux PerkinElmer 
Nanodrop ND1000 Wilmington 
Nucleofector II Amaxa 
Synergy HT reader BioTek 




AxioVision Carl Zeiss 
Endnote Thomson Reuters 
FACSDiva Software BD Bioscience 
FlowJo Tree Star 
Gen5 BioTek 
Prism Graph Pad Software 
Leica Application Suite Leica 
 
5.2. Methods 
5.2.1. Infections and quantification of parasite burden 
E. falciformis oocysts were purified by flotation in NaOCl as described elsewhere (12). For 
experimental infections, mice aged 10-14 weeks were inoculated with 50 E. falciformis 
oocysts in 100 µl water via oral gavage, weighed daily and sacrificed at the end of patency, or 
at d 10 p. i. where indicated. Mice were euthanised upon 20 % body weight loss. For analysis 
of challenge infections, mice received a dose of 10 oocysts followed by a challenge infection 
with 50 oocysts four weeks after the primary dose. During patency faeces were collected 
every 24 h (± 2 h), soaked in water, homogenised and floated in saturated NaCl solution. The 
number of oocysts was quantified using a McMaster chamber. 
 
5.2.2. Neutralisation of cytokines 
For in vivo neutralisation of IL-17A and / or IL-22, 200 µg of anti-IL-17A (MM17AF3, 
Catherine Uyttenhove, Brussels) and / or anti-IL-22 (AM22.1, Jean-Christophe Renauld, 
Brussels) monoclonal antibody in PBS were injected intraperitoneally into mice on day -1, 2, 
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5 and 8 p. i. Control groups received 200 µg mouse IgG control antibody (Dianova) according 
to the same treatment regimen. 
 
5.2.3. Histology 
For histopathological analysis, colon and caecum samples were fixed with 3.7% 
paraformaldehyde and embedded in paraffin. 2 µm sections were cut, deparaffinised and 
stained with hematoxylin and eosin (H&E). Periodic acid-schiff (PAS) histochemistry was 
conducted in a Dako Autostainer plus (Dako) according to the manufacturer´s instructions. E. 
falciformis was quantified in PAS stained caecal thin sections from d 5 p. i. by counting the 
number of mature schizonts per high power field (HPF, 400 x magnification, 20 replicates). 
Images were acquired using an AxioImager Z1 microscope equipped with a charge-coupled 
device (CCD) camera (AxioCam MRm) and processed with AxioVision software (all 
purchased from Carl Zeiss MicroImaging, Inc.).  
 
5.2.4. In vitro culture of E. falciformis in cell lines 
CMT-93 cells (ATCC No. CCL-223, a gift from T. Schüler, Berlin) were cultured in DMEM 
supplemented with 10 % FCS, 20 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml 
streptomycin. Cells were harvested using 1x Trypsin/EDTA solution (PAA laboratories) and 
incubated with 2 µg/ml Mitomycin C (Applichem) for 30 min at 37 °C to inhibit proliferation. 
After washing, cells were resuspended in media containing 50 ng/ml of the respective 
cytokine (IFN-γ, IL-17A, IL-22, IL-10, Il-13 and IL-4 Peprotech) and 5 x 105 cells were 
seeded in 24 well plates on cover slips (ø 12 mm). E. falciformis sporozoites were purified as 
described before (152), and 8 h after seeding cells were infected with 1 x 105 E. falciformis 
sporozoites suspended in DMEM without FCS. Extracellular parasites were washed off 4 h 
post infection and DMEM with 10 % FCS was added for further culture. For histological 
examination, monolayers were fixed for 10 min using 4 % paraformaldehyde and stained with 
periodic acid-Schiff. Invasion was determined 4 h p. i. by counting intracellular 
sporozoites/HPF (400x magnification, 10 HPFs per sample). Development was assessed at 39 
h p. i. by scanning the whole cover slip for mature schizonts. Infection of VERO cells, 
STAT1-/- cells and HFF cells was done similar. 6 x 104 VERO, HFF or STAT1-/- cells seeded 
directly onto cover slips in 24 well plates were infected at a MOI of 3 and monitored after 4 
and 72 h p. i.  
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5.2.5. Lymphocyte isolation and culture 
Mesenteric lymph nodes and spleens were isolated from euthanised mice and single cell 
suspensions were obtained by passing through a 70 µm cell strainer (BD Biosciences). Cells 
were resuspended in complete RPMI and counted using a Casy Model TT cell counter 
(Innovatis). Lamina propria lymphocytes (LPL) were isolated from the caecum and proximal 
colon. Briefly, mesenteric fat and the caecal patch were removed and the intestine opened 
longitudinally, washed thoroughly in HBSS containing 2% FCS and cleaned further by 
vigorous shaking in the same buffer two times. Epithelial cells were removed by a 20 min 
incubation in HBSS 2% FCS containing 2mM EDTA. Tissue was then minced and incubated 
for 1 hour at 37 °C in RPMI medium containing 10% FCS, 200 U/ml Collagenase VIII and 
0.1U/ml Collagenase D (Sigma-Aldrich). The digested tissue was filtered, centrifuged and the 
cell pellet resuspended and layered onto a 40% / 70% Percoll gradient (GE Healthcare) and 
centrifuged for 20 min at 2000 rpm. LPL were isolated from the interface and analysed by 
flow cytometry. 
 
5.2.6. Lymphocyte restimulations 
5 × 105 MLN cells were cultured in a total volume of 200 µl in 96 well round bottom plates in 
complete RPMI containing 10 % fetal calf serum, 20 mM L-glutamine, 100 U/ml penicillin 
and 100 µg/ml streptomycin (PAA laboratories). Cultures were restimulated with total 
sporozoite antigen equivalent to 1.2 x 105 sporozoites/well as described before (12) or 1µg/ml 
anti-CD3 antibody (BD Biosciences) at 37 °C and 5% CO2 for 48 h. Supernatants were 
harvested for cytokine detection and in some experiments medium was replaced and 1 µCi of 
methyl-[3H]-thymidine (Amersham Pharmacia Biotech) was added. Cultures were placed at 
37 °C and 5% CO2 for additional 20 h to measure radiolabelled thymidine incorporation 
which was detected using a 1450 MicroBeta TriLux Microplate Scintillation and 
Luminescence Counter according to the manufacturers instructions (PerkinElmer). 
 
5.2.7. Flow cytometric analysis 
The following mouse monoclonal antibodies were used for flow cytometry: CD8-PE, GR-1-
Cy5 (DRFZ, Berlin), CD4-FITC, IL-17A-PE, CD25-APC, CD103-PE (BD Biosciences), 
RORgt-APC, T-bet-PE, CD49b-PE-Cy7, IL-17A-FITC, IL-22-PE, IFN-γ-PacBlue, CD4-
PercP-eF710, FoxP3-eF450 (eBioscience) and Ly-6C-PacBlue (BioLegend) in pre-titrated 
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concentrations. For intracellular detection of IFN-γ, IL-17A and IL-22, 5 × 106 cells were 
restimulated in 1 ml complete RPMI in 48 well plates with 50 ng/ml PMA and 1 µg/ml 
ionomycin for 3 h at 37 °C and 5 % CO2. After 30 min of initial incubation 5 µg/ml brefeldin 
A was added. Subsequently, intracellular cytokines were detected using the Cytofix/Cytoperm 
kit (BD Biosciences). Fixation/Permeabilisation buffers (eBioscience) were used for 
intracellular detection of cytokines in combination with FoxP3, T-bet or RORγt. Stained cells 




Cytokines were quantified in cell culture supernatants in duplicates using an IFN-γ ELISA 
(eBioscience) and IL-22, IL-17A DuoSet ELISA (R&D Systems) according to the 
manufacturers instructions. ELISA plates were read with a Synergy HT reader together with 
Gen5 Data Analysis Software (BioTek). 
 
5.2.9. Quantitative real time PCR 
Caecum samples were snap frozen in liquid nitrogen and stored at -80 °C. The tissue was 
homogenised using a tissue homogeniser (MP Biomedicals), samples were centrifuged (10 
min, 20000×g, 4° C) and total RNA was isolated from lysed CMT-93 cells or caecum tissue 
using an innuPREP RNA kit according to the manufacturer’s instructions (Analytik Jena). 
Following reverse transcription of 2 µg RNA using the High Capacity RNA-to-cDNA Kit 
(Applied Biosystems), quantitative real time PCR was performed in duplicates with 10 ng of 
cDNA using the FastStart Universial SYBR Green Master Mix (Roche) in an ABI 7300 Real-
time PCR System (Applied Biosystems). A list of used primers (MWG Biotech) can be found 
in section 5.1.6. Following normalisation to beta-actin (house keeping gene), the results were 
plotted as relative expression compared to naïve controls using the 2-ΔΔCt method. 
 
5.2.10. Cloning 
The Dream-Taq Polymerase (Fermentas) was used to amplify 10-500 ng template DNA in 
standard PCR in a Mastercycler (Eppendorf). The Pfu-Ultra FusionII polymerase (Stratagene) 
was used for cloning. PCR settings were adjusted according to the primers used and to the 
expected product size. PCR products were analysed using 0.8-1.5 % agarose gels containing 
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0.4 % ethidium bromide. Gels were run at 80-100 V in TAE buffer and visualised by UV 
light. PCR products of interest (inserts) were purified from agarose gels using the innuPrep 
gel extraction kit (JenaAnalytik) according to the manufacturers instructions. Vectors for 
ligation were purified from E. coli using the innuPrep Plasmid Mini Kit (JenaAnalytik). After 
measuring DNA concentration (Nanodrop), the desired amounts of vector and insert were 
digested with the appropriate enzymes. For non-directional cloning the insert was 
dephosphorylated using Antarctic Phosphatase (NEB) according to the manual. Ligation of 
the digested vector and the insert (10 fmol vector and 30-50 fmol insert) was performed for 1 
h at RT using 1U of T4 ligase (Invitrogen). The product was transformed into a tenfold higher 
volume of competent E. coli XL1 blue by incubation on ice for 30 min, followed by a heat 
shock for 45s at 42 °C. Cells were left on ice for 2 min before prewarmed SOC medium was 
added. The culture was placed on a shaker at 37 °C for 1 h. Cells were pelleted, resuspended 
in fresh LB medium and plated onto agar plates containing ampicillin or kanamycin for 
overnight culture at 37 °C. 
 
5.2.11. Plasmids 
The initially used plasmids pmic1YFPmYFPact and pactDHTSact were obtained from Fiona 
Tomley (IAH, Compton, UK). Restriction digest and sequencing revealed that only a single 
copy of the YFP gene is present in pmic1YFPmYFPact, which was therefore renamed to 
pmic1YFPmact (data not shown). Plasmids were transformed into E. coli XL1 blue, incubated 
overnight and subsequently grown to an OD of 0.6 in the desired volume LB medium (e. g. 
200 ml). Plasmids were purified using the Nucleobond EF Midi Prep Kit from Machery & 
Nagel. The number of molecules was calculated from the number of base pairs of each 
plasmid, and 1012 plasmid copies (for example 22 µg pDHTSrevYFP) were used for 
transfection unless stated otherwise. This method guarantees equal plasmid copy number in 
transfection with plasmids of different sizes. The following enzymes were used for 
linearisation of plasmids (next page): 




Plasmid Plasmid size (bp) Approx. amount [µg] for 
1012 plasmid copies 
Restriction          
enzyme for 
linearisation 
pmic1YFPmact 5232 11 PsiI 
pactDHTSact 7598 16 HindIII 
pDHTSYFP 9608 22 HindIII 
prevDHTSYFP 9608 22 HindIII 
pDHTSrevYFP 9608 22 HindIII 
pactDHTSlinkYFPact 8337 18 SapI 
p18s+DHTSrevYFP 11402 24 SapI 
p18s-DHTSrevYFP 11402 24 SapI 
 
5.2.12. Transfection of unsporulated oocysts 
NMRI mice were infected with 300 wild type oocysts and faeces were collected on d 8 p. i. 
Oocysts were purified from homogenised faeces by passing them through a 40 µm metal 
sieve followed by flotation in NaOCl. After three washes in deionised water, oocysts were 
passed through a 30 µm cell strainer. Oocysts were either left untreated or incubated in 
NaOCl for 15 or 30 min on ice prior to electroporation in 100 µl Basic Parasite Nucleofector 
Solution 1 or 2 (Amaxa) supplemented with 5 µg pmic1YFPmact and 10 U PsiI (REMI) in an 
Amaxa Nucleofector II (programm U-033). 
 
Transfection Kit (Amaxa®) Treatment before transfection 
Sporulation 
rate [%] 
Basic Parasite Nucleofector Kit 1 
No treatment 83 
NaOCl 15 min on ice 92 
NaOCl 30 min on ice 95 
Basic Parasite Nucleofector Kit 2 
No treatment 91 
NaOCl 30 min on ice 83 
NaOCl 60 min on ice 91 
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5.2.13. Transfection of sporozoites 
2 x 106 Sporozoites were resuspended in 100 µl complete cytomix or in Basic Parasite 
Nucleofector Solution 1 (Amaxa), containing 1012 molecules of the used plasmid unless stated 
otherwise. Sporozoites were transfected in an Amaxa Nucleofector II using programm U-033. 
500 µl culture medium were added immediately after transfection and 200 µl of the 
sporozoite suspension was administered rectally to mice (approximately 6.5 x 105 
sporozoites) or onto cell monolayers in the desired concentration. 
 
5.2.14. Rectal infection of mice 
20 min prior to infection 200 µl PBS were injected rectally into mice using an umbilical 
catheter (Vycon, France). Subsequently, mice were infected rectally with 6.5 x 105 
sporozoites using an umbilical catheter and kept vertically on their forefeet for few seconds. 
 
5.2.15. Treatment of mice with pyrimethamine 
The drug was applied from d 1 to d 6 p. i. Mice were weighed prior to treatment to calculate 
the exact dosage. For standard treatment of mice, pyrimethamine was dissolved in a mixture 
of DMSO and PEG400 (2:1) by vigorous vortexing and the appropriate concentration of 
pyrimethamine in DMSO/PEG400 was adjusted to 170 µl to ensure that equal amounts of the 
solvent are administered to mice (Sandra Schorderet Weber, Novartis Animal Health, 
personal communication). During the establishment of the selection system, pyrimethamine 
was first dissolved in DMSO at a concentration of 7 mg/ml and diluted 100-fold in the 
drinking water of mice. For application as an aqueous suspension, pyrimethamine was 
homogenised in a 50 ml tube using a glas stick and suspended in tap water at the desired 
concentration. 0.5 ml of this suspension was administered to mice using oral gavage. For 
application as an emulsion in Cremophor EL (Bayer), pyrimethamine was suspended in the 
emulgator and then further diluted in tap water to the desired concentration. 0.5 ml of this 
suspension was administered to mice using oral gavage. For i. p. administration, 
pyrimethamine was dissolved in EtOH or in DMSO/PEG400 (see above). For treatment of 
mice with pyrimethamine in diet special food, containing 200, 400 or 600 ppm of the drug 
were provided to the mice ad libitum. Pyrimethamine / 2-hydroxypropyl-β-cyclodextrin 
inclusion complexes were prepared as described before (144). Briefly, a physical mixture of 
pyrimethamine and 2-hydroxypropyl-β-cyclodextrin (HPBCD) was prepared 
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(Pyr=0.101+0.1865*HPBCD) and stirred for 48 h protected from light. The solution was 
centrifuged at max speed (4500xg) for 10 min and the supernatant was sterile filtered prior to 
storage at 4 °C. 
 
5.2.16. FACS sorting and manual selection of YFP+ oocysts 
Oocysts were purified from homogenised faeces on d 8 p. i. by passing them through a 40 µm 
metal sieve followed by flotation in NaOCl. After three washes in deionised water, oocysts 
were again passed through a 30 µm cell strainer and resuspended in 500 µl deionised water. A 
BD Aria II sorter was used for sorting of YFP+ oocysts (488 nm laser) and data were 
analysed using FlowJo (Tree Star). For manual selection, oocysts were placed in a µ-dish 
(IBIDI) and screened at 200x or 400x magnification. YFP+ oocysts were aspirated gently 
from the oocyst suspension using a custom made, very thin glas pasteur pipette and 
transferred to a drop of deionised water in a new dish. This was again screened and sorting 
was repeated until the drop contained only YFP+ oocysts. 
 
5.2.17. Detection of YFP in purified genomic DNA from oocysts 
Oocysts were purified using NaOCl and resuspended in deionised water. Extraction of DNA 
was performed as described previously for E. nieschulzi (153). The following primers were 
used for detection of the YFP gene by PCR: 
YFP forward: CATCCGACTTCAATCGTCTCACAG 
YFP reverse: ACAGGCAGCACACAATAACGC 
 
5.2.18. Tracking of YFP+ life cycle stages ex vivo and in vitro 
For ex vivo imaging of YFP+ life cycle stages, NMRI mice were infected with 6 x 104 YFP+ 
oocysts that had been sorted using FACS. Mice were dissected at 120 h p. i. to observe mature 
schizonts and at 190 h p. i. to detect oocysts. The caecum was opened longitudinally and 
washed in PBS. A small piece of tissue was placed on an object slide with the inner layer of 
the intestine facing up and kept moist using PBS. The sample was imaged through a glass 
coverslip using a Zeiss AxioImager Z2 and pictures were analysed using AxioVision software 
(Zeiss). For in vitro imaging of YFP+ life cycle stages, VERO cells were seeded in a µDish 
Grid-500 (IBIDI) that contains an engraved grid in the glas bottom. Cell monolayers were 
inoculated with purified YFP+ E. falciformis sporozoites and screened for YFP+ parasites at 
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various time points using a DMIL inverted fluorescence microscope (Leica). Using the grid, 
development of single parasites could be tracked over the whole observation period. 
 
5.2.19. Infection of C57BL/6 EGFP mice and adoptive transfer 
C57BL/6 EGFP mice were infected with 50 E. falciformis oocysts and faeces were collected 
from d 8-10 p. i. Oocyst counts were compared to an equally treated C57BL/6 wild type 
group. The mice were challenge with 50 E. falciformis oocysts four weeks after primary 
infection. The number of shed oocysts from d 8-10 p. i. was determined. This was repeated 
once more (third infection). For adoptive transfer experiments, EGFP mice were infected with 
50 E. falciformis oocysts and dissected at day 10 p. i. MLN and spleen cells were isolated and 
transferred to naïve C57BL/6 wild type recipients that were challenged with 50 E. falciformis 
oocysts 24 h later. Two days after transfer, recipient mice were dissected and MLN and 
spleen cells were analysed for YFP-expression using FACS. 
 
5.2.20. Statistics 
The nonparametric Mann-Whitney U test was used for statistical analysis. Values of p ≤ 0.05 
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